EA201492222A1 - Способы конструирования неаллореактивной и устойчивой к иммуносупрессии т-клетки для иммунотерапии - Google Patents

Способы конструирования неаллореактивной и устойчивой к иммуносупрессии т-клетки для иммунотерапии

Info

Publication number
EA201492222A1
EA201492222A1 EA201492222A EA201492222A EA201492222A1 EA 201492222 A1 EA201492222 A1 EA 201492222A1 EA 201492222 A EA201492222 A EA 201492222A EA 201492222 A EA201492222 A EA 201492222A EA 201492222 A1 EA201492222 A1 EA 201492222A1
Authority
EA
Eurasian Patent Office
Prior art keywords
cells
methods
immunotherapy
nonalloactive
immunosupression
Prior art date
Application number
EA201492222A
Other languages
English (en)
Russian (ru)
Inventor
Роман Галетто
Аньес Губль
Стефани Гросс
Сесиль Манниуи
Лоран Пуаро
Эндрю Шаренберг
Джулианна Смит
Original Assignee
Селлектис
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=48579464&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=EA201492222(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Селлектис filed Critical Селлектис
Publication of EA201492222A1 publication Critical patent/EA201492222A1/ru

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0634—Cells from the blood or the immune system
    • C12N5/0636—T lymphocytes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/14—Blood; Artificial blood
    • A61K35/17—Lymphocytes; B-cells; T-cells; Natural killer cells; Interferon-activated or cytokine-activated lymphocytes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/10—Cellular immunotherapy characterised by the cell type used
    • A61K40/11—T-cells, e.g. tumour infiltrating lymphocytes [TIL] or regulatory T [Treg] cells; Lymphokine-activated killer [LAK] cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/30—Cellular immunotherapy characterised by the recombinant expression of specific molecules in the cells of the immune system
    • A61K40/31—Chimeric antigen receptors [CAR]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/40—Cellular immunotherapy characterised by antigens that are targeted or presented by cells of the immune system
    • A61K40/41—Vertebrate antigens
    • A61K40/42—Cancer antigens
    • A61K40/4202—Receptors, cell surface antigens or cell surface determinants
    • A61K40/421—Immunoglobulin superfamily
    • A61K40/4211—CD19 or B4
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/38—Drugs for disorders of the endocrine system of the suprarenal hormones
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503—Immunoglobulin superfamily
    • C07K14/7051—T-cell receptor (TcR)-CD3 complex
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503—Immunoglobulin superfamily
    • C07K14/70517—CD8
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503—Immunoglobulin superfamily
    • C07K14/70521—CD28, CD152
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70578—NGF-receptor/TNF-receptor superfamily, e.g. CD27, CD30, CD40, CD95
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2121/00—Preparations for use in therapy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/10—Immunoglobulins specific features characterized by their source of isolation or production
    • C07K2317/14—Specific host cells or culture conditions, e.g. components, pH or temperature
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/569—Single domain, e.g. dAb, sdAb, VHH, VNAR or nanobody®
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
    • C07K2317/622—Single chain antibody (scFv)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
    • C07K2319/03—Fusion polypeptide containing a localisation/targetting motif containing a transmembrane segment
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/70—Fusion polypeptide containing domain for protein-protein interaction
    • C07K2319/74—Fusion polypeptide containing domain for protein-protein interaction containing a fusion for binding to a cell surface receptor
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/30—Hormones
    • C12N2501/38—Hormones with nuclear receptors
    • C12N2501/39—Steroid hormones
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/50—Cell markers; Cell surface determinants
    • C12N2501/51—B7 molecules, e.g. CD80, CD86, CD28 (ligand), CD152 (ligand)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/50—Cell markers; Cell surface determinants
    • C12N2501/515—CD3, T-cell receptor complex
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/50—Cell markers; Cell surface determinants
    • C12N2501/599—Cell markers; Cell surface determinants with CD designations not provided for elsewhere
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2502/00—Coculture with; Conditioned medium produced by
    • C12N2502/99—Coculture with; Conditioned medium produced by genetically modified cells
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2510/00—Genetically modified cells

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Engineering & Computer Science (AREA)
  • Zoology (AREA)
  • Biochemistry (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Cell Biology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biomedical Technology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Toxicology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biotechnology (AREA)
  • Wood Science & Technology (AREA)
  • Epidemiology (AREA)
  • Hematology (AREA)
  • General Engineering & Computer Science (AREA)
  • Microbiology (AREA)
  • Oncology (AREA)
  • Virology (AREA)
  • Communicable Diseases (AREA)
  • Developmental Biology & Embryology (AREA)
  • Plant Pathology (AREA)
  • Physics & Mathematics (AREA)
  • Transplantation (AREA)
  • Physical Education & Sports Medicine (AREA)
EA201492222A 2012-05-25 2013-05-13 Способы конструирования неаллореактивной и устойчивой к иммуносупрессии т-клетки для иммунотерапии EA201492222A1 (ru)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201261651933P 2012-05-25 2012-05-25
US201261696612P 2012-09-04 2012-09-04
PCT/US2013/040755 WO2013176915A1 (en) 2012-05-25 2013-05-13 Methods for engineering allogeneic and immunosuppressive resistant t cell for immunotherapy

Publications (1)

Publication Number Publication Date
EA201492222A1 true EA201492222A1 (ru) 2015-05-29

Family

ID=48579464

Family Applications (1)

Application Number Title Priority Date Filing Date
EA201492222A EA201492222A1 (ru) 2012-05-25 2013-05-13 Способы конструирования неаллореактивной и устойчивой к иммуносупрессии т-клетки для иммунотерапии

Country Status (25)

Country Link
US (15) US10426795B2 (https=)
EP (7) EP3276000A3 (https=)
JP (5) JP6463672B2 (https=)
KR (2) KR102437522B1 (https=)
CN (3) CN108998418A (https=)
AR (1) AR096274A1 (https=)
AU (5) AU2013266733B2 (https=)
BR (1) BR112014029417B1 (https=)
CA (3) CA2874609C (https=)
DK (2) DK2855667T5 (https=)
EA (1) EA201492222A1 (https=)
ES (2) ES2962571T3 (https=)
HK (1) HK1245321A1 (https=)
HU (2) HUE070380T2 (https=)
IN (1) IN2014DN10991A (https=)
MA (1) MA37681B2 (https=)
MX (1) MX370265B (https=)
MY (1) MY180127A (https=)
NZ (1) NZ703281A (https=)
PL (2) PL2855667T3 (https=)
PT (2) PT3473707T (https=)
SG (2) SG11201407802WA (https=)
UA (1) UA118652C2 (https=)
WO (2) WO2013176916A1 (https=)
ZA (1) ZA201409536B (https=)

Cited By (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11365226B2 (en) 2016-09-08 2022-06-21 2Seventy Bio, Inc. PD-1 homing endonuclease variants, compositions, and methods of use
RU2781083C2 (ru) * 2016-09-08 2022-10-05 2сэвэнти био, Инк. Варианты, композиции и методы применения хоминг-эндонуклеазы pd-1
US12404500B2 (en) 2018-12-10 2025-09-02 Novo Nordisk A/S Homing endonuclease variants
US12577547B2 (en) 2018-12-10 2026-03-17 Regeneron Pharmaceuticals, Inc. PDCD-1 homing endonuclease variants

Families Citing this family (448)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9273283B2 (en) * 2009-10-29 2016-03-01 The Trustees Of Dartmouth College Method of producing T cell receptor-deficient T cells expressing a chimeric receptor
US10323236B2 (en) 2011-07-22 2019-06-18 President And Fellows Of Harvard College Evaluation and improvement of nuclease cleavage specificity
US10704021B2 (en) 2012-03-15 2020-07-07 Flodesign Sonics, Inc. Acoustic perfusion devices
US9458450B2 (en) 2012-03-15 2016-10-04 Flodesign Sonics, Inc. Acoustophoretic separation technology using multi-dimensional standing waves
US10967298B2 (en) 2012-03-15 2021-04-06 Flodesign Sonics, Inc. Driver and control for variable impedence load
US9950282B2 (en) 2012-03-15 2018-04-24 Flodesign Sonics, Inc. Electronic configuration and control for acoustic standing wave generation
BR112014029417B1 (pt) 2012-05-25 2023-03-07 Cellectis Método ex vivo para a preparação de células t para imunoterapia
US20150017136A1 (en) * 2013-07-15 2015-01-15 Cellectis Methods for engineering allogeneic and highly active t cell for immunotherapy
AU2013329186B2 (en) * 2012-10-10 2019-02-14 Sangamo Therapeutics, Inc. T cell modifying compounds and uses thereof
EP4282419A1 (en) 2012-12-20 2023-11-29 Purdue Research Foundation Chimeric antigen receptor-expressing t cells as anti-cancer therapeutics
DK2956175T3 (da) 2013-02-15 2017-11-27 Univ California Kimærisk antigenreceptor og fremgangsmåder til anvendelse deraf
US9587237B2 (en) 2013-03-14 2017-03-07 Elwha Llc Compositions, methods, and computer systems related to making and administering modified T cells
CA2905352A1 (en) * 2013-03-14 2014-09-25 Bellicum Pharmaceuticals, Inc. Methods for controlling t cell proliferation
US9499855B2 (en) 2013-03-14 2016-11-22 Elwha Llc Compositions, methods, and computer systems related to making and administering modified T cells
JP6005572B2 (ja) * 2013-03-28 2016-10-12 Kddi株式会社 動画像符号化装置、動画像復号装置、動画像符号化方法、動画像復号方法、およびプログラム
WO2014165707A2 (en) 2013-04-03 2014-10-09 Memorial Sloan-Kettering Cancer Center Effective generation of tumor-targeted t-cells derived from pluripotent stem cells
US11311575B2 (en) * 2013-05-13 2022-04-26 Cellectis Methods for engineering highly active T cell for immunotherapy
US11077144B2 (en) 2013-05-13 2021-08-03 Cellectis CD19 specific chimeric antigen receptor and uses thereof
US20230056268A1 (en) * 2013-05-13 2023-02-23 Cellectis Methods for engineering highly active t cell for immunotheraphy
US20230050345A1 (en) * 2013-05-13 2023-02-16 Cellectis Methods for engineering allogeneic and highly active t cell for immunotheraphy
EP3783098A1 (en) 2013-05-14 2021-02-24 Board Of Regents, The University Of Texas System Human application of engineered chimeric antigen receptor (car) t-cells
ES2883131T3 (es) 2013-05-29 2021-12-07 Cellectis Métodos para la modificación de células T para inmunoterapia utilizando el sistema de nucleasa CAS guiado por ARN
WO2014191128A1 (en) 2013-05-29 2014-12-04 Cellectis Methods for engineering t cells for immunotherapy by using rna-guided cas nuclease system
US10208125B2 (en) 2013-07-15 2019-02-19 University of Pittsburgh—of the Commonwealth System of Higher Education Anti-mucin 1 binding agents and uses thereof
US9163284B2 (en) 2013-08-09 2015-10-20 President And Fellows Of Harvard College Methods for identifying a target site of a Cas9 nuclease
US9359599B2 (en) 2013-08-22 2016-06-07 President And Fellows Of Harvard College Engineered transcription activator-like effector (TALE) domains and uses thereof
US9322037B2 (en) 2013-09-06 2016-04-26 President And Fellows Of Harvard College Cas9-FokI fusion proteins and uses thereof
US9526784B2 (en) 2013-09-06 2016-12-27 President And Fellows Of Harvard College Delivery system for functional nucleases
US9228207B2 (en) 2013-09-06 2016-01-05 President And Fellows Of Harvard College Switchable gRNAs comprising aptamers
CN106459995B (zh) 2013-11-07 2020-02-21 爱迪塔斯医药有限公司 使用统治型gRNA的CRISPR相关方法和组合物
EP3071686B1 (en) * 2013-11-22 2020-07-22 Cellectis SA Method for generating batches of allogeneic t-cells with averaged potency
WO2015075195A1 (en) * 2013-11-22 2015-05-28 Cellectis Method of engineering chemotherapy drug resistant t-cells for immunotherapy
RU2689558C1 (ru) * 2013-11-22 2019-05-28 Селлектис Способ конструирования аллогенных и устойчивых к лекарственным препаратам т-клеток для иммунотерапии
WO2015077717A1 (en) 2013-11-25 2015-05-28 The Broad Institute Inc. Compositions and methods for diagnosing, evaluating and treating cancer by means of the dna methylation status
WO2015085147A1 (en) 2013-12-05 2015-06-11 The Broad Institute Inc. Polymorphic gene typing and somatic change detection using sequencing data
US20150165054A1 (en) 2013-12-12 2015-06-18 President And Fellows Of Harvard College Methods for correcting caspase-9 point mutations
KR20230076867A (ko) 2013-12-20 2023-05-31 더 브로드 인스티튜트, 인코퍼레이티드 신생항원 백신과의 병용 요법
WO2015092024A2 (en) * 2013-12-20 2015-06-25 Cellectis Method of engineering multi-input signal sensitive t cell for immunotherapy
WO2015105955A1 (en) 2014-01-08 2015-07-16 Flodesign Sonics, Inc. Acoustophoresis device with dual acoustophoretic chamber
ES2701846T3 (es) * 2014-01-14 2019-02-26 Cellectis Receptor de antígeno quimérico que usa dominios de reconocimiento de antígenos derivados de pez cartilaginoso
EP3690044B1 (en) 2014-02-11 2024-01-10 The Regents of the University of Colorado, a body corporate Crispr enabled multiplexed genome engineering
KR102375998B1 (ko) * 2014-02-14 2022-03-21 더 보드 오브 리젠츠 오브 더 유니버시티 오브 텍사스 시스템 키메라 항원 수용체 및 제조방법
WO2015121454A1 (en) * 2014-02-14 2015-08-20 Cellectis Cells for immunotherapy engineered for targeting antigen present both on immune cells and pathological cells
US10934346B2 (en) 2014-02-14 2021-03-02 Bellicum Pharmaceuticals, Inc. Modified T cell comprising a polynucleotide encoding an inducible stimulating molecule comprising MyD88, CD40 and FKBP12
CA2939711C (en) * 2014-02-21 2020-09-29 Cellectis Method for in situ inhibition of regulatory t cells
DK3241561T3 (da) * 2014-03-05 2025-06-30 Autolus Ltd Konjugeret antistof eller bispecifik t-celle-engager, som selektivt binder enten tcr-beta konstant region 1 (trbc1) eller trbc2
US11982673B2 (en) 2014-03-05 2024-05-14 Autolus Limited Methods
US11385233B2 (en) 2015-03-05 2022-07-12 Autolus Limited Methods of depleting malignant T-cells
JP6681837B2 (ja) 2014-03-11 2020-04-15 セレクティスＣｅｌｌｅｃｔｉｓ 同種移植に適合するｔ細胞を作製するための方法
PL3119807T3 (pl) 2014-03-19 2019-09-30 Cellectis Specyficzne wobec cd123 chimeryczne receptory antygenowe do immunoterapii nowotworów
CN106795221B (zh) 2014-04-03 2022-06-07 塞勒克提斯公司 用于癌症免疫治疗的cd33特异性嵌合抗原受体
JP2017513472A (ja) * 2014-04-11 2017-06-01 セレクティスＣｅｌｌｅｃｔｉｓ アルギニンおよび／またはトリプトファン枯渇微小環境に対して抵抗性を有する免疫細胞を作製するための方法
EP3131927B8 (en) 2014-04-14 2020-12-23 Cellectis Bcma (cd269) specific chimeric antigen receptors for cancer immunotherapy
WO2015161276A2 (en) * 2014-04-18 2015-10-22 Editas Medicine, Inc. Crispr-cas-related methods, compositions and components for cancer immunotherapy
US20170051037A1 (en) 2014-05-02 2017-02-23 Cellectis Cs1 specific multi-chain chimeric antigen receptor
KR20170032406A (ko) 2014-07-15 2017-03-22 주노 쎄러퓨티크스 인코퍼레이티드 입양 세포 치료를 위한 조작된 세포
WO2016016344A1 (en) 2014-07-29 2016-02-04 Cellectis Ror1(ntrkr1)specific chimeric antigen receptors for cancer immunotherapy
US10077453B2 (en) 2014-07-30 2018-09-18 President And Fellows Of Harvard College CAS9 proteins including ligand-dependent inteins
US10544201B2 (en) 2014-07-31 2020-01-28 Cellectis ROR1 specific multi-chain chimeric antigen receptor
PT3177640T (pt) 2014-08-08 2020-08-31 Univ Leland Stanford Junior Agentes pd-1 de alta afinidade e métodos de utilização
AU2015312117A1 (en) 2014-09-02 2017-03-02 Bellicum Pharmaceuticals, Inc. Costimulation of chimeric antigen receptors by Myd88 and CD40 polypeptides
EP3189073B2 (en) 2014-09-04 2025-06-11 Cellectis Trophoblast glycoprotein (5t4, tpbg) specific chimeric antigen receptors for cancer immunotherapy
EP3209679A1 (en) * 2014-10-24 2017-08-30 BCRT Holding BV T cell-based immunotherapeutics
US20170335331A1 (en) * 2014-10-31 2017-11-23 The Trustees Of The University Of Pennsylvania Altering Gene Expression in CART Cells and Uses Thereof
ES2987570T3 (es) * 2014-11-05 2024-11-15 Juno Therapeutics Inc Métodos para la transducción y el procesamiento de células
GB201421096D0 (en) * 2014-11-27 2015-01-14 Imp Innovations Ltd Genome editing methods
EP3234130B1 (en) 2014-12-19 2020-11-25 The Broad Institute, Inc. Methods for profiling the t-cell- receptor repertoire
US10975442B2 (en) 2014-12-19 2021-04-13 Massachusetts Institute Of Technology Molecular biomarkers for cancer immunotherapy
WO2016123100A1 (en) 2015-01-26 2016-08-04 Fate Therapeutics, Inc. Methods and compositions for inducing hematopoietic cell differentiation
BR112017013981A2 (pt) 2015-01-26 2018-01-02 Cellectis receptores antigênicos quiméricos com uma única cadeia específicos anti-cll1 (sccars) para imunoterapia de câncer
US10557140B2 (en) * 2015-02-02 2020-02-11 Industry-Academic Cooperation Foundation, Dankook University CTLA-4-targeting trans-splicing ribozyme for delivery of chimeric antigen receptor, and use thereof
WO2016124765A1 (en) * 2015-02-06 2016-08-11 Cellectis Primary hematopoietic cells genetically engineered by slow release of nucleic acids using nanoparticles
US20170151281A1 (en) 2015-02-19 2017-06-01 Batu Biologics, Inc. Chimeric antigen receptor dendritic cell (car-dc) for treatment of cancer
KR102624023B1 (ko) 2015-02-24 2024-01-11 더 리젠츠 오브 더 유니버시티 오브 캘리포니아 결합-촉발된 전사 스위치 및 이들의 이용 방법
WO2016138846A1 (en) * 2015-03-02 2016-09-09 Shanghai Sidansai Biotechnology Co., Ltd Reducing immune tolerance induced by pd‐l1
JP2018509148A (ja) * 2015-03-11 2018-04-05 セレクティスＣｅｌｌｅｃｔｉｓ 患者における持続性および／または生着を増加させるために同種ｔ細胞を改変する方法
US20180072990A1 (en) * 2015-03-20 2018-03-15 Children's National Medical Center Generating virus or other antigen-specific t cells from a naïve t cell population
GB201504840D0 (en) * 2015-03-23 2015-05-06 Ucl Business Plc Chimeric antigen receptor
AU2016243583B2 (en) * 2015-03-27 2022-03-10 President And Fellows Of Harvard College Modified T cells and methods of making and using the same
WO2016166268A1 (en) 2015-04-17 2016-10-20 Cellectis Engineering animal or plant genome using dna-guided argonaute interference systems (dais) from mesophilic prokaryotes
US11021699B2 (en) 2015-04-29 2021-06-01 FioDesign Sonics, Inc. Separation using angled acoustic waves
US11708572B2 (en) 2015-04-29 2023-07-25 Flodesign Sonics, Inc. Acoustic cell separation techniques and processes
US11377651B2 (en) 2016-10-19 2022-07-05 Flodesign Sonics, Inc. Cell therapy processes utilizing acoustophoresis
WO2016179319A1 (en) * 2015-05-04 2016-11-10 Cellerant Therapeutics, Inc. Chimeric antigen receptors with ctla4 signal transduction domains
CN107921148A (zh) 2015-05-08 2018-04-17 哈佛学院校长同事会 通用供体干细胞和相关方法
AU2016261927B2 (en) * 2015-05-12 2022-04-07 Sangamo Therapeutics, Inc. Nuclease-mediated regulation of gene expression
PL3298033T5 (pl) * 2015-05-18 2023-10-30 TCR2 Therapeutics Inc. Kompozycje i zastosowania medyczne do reprogramowania TCR z zastosowaniem białek fuzyjnych
US10752670B2 (en) 2015-05-20 2020-08-25 Cellectis Anti-GD3 specific chimeric antigen receptors for cancer immunotherapy
IL294183B2 (en) 2015-05-20 2023-10-01 Dana Farber Cancer Inst Inc shared neoantigens
WO2016196388A1 (en) 2015-05-29 2016-12-08 Juno Therapeutics, Inc. Composition and methods for regulating inhibitory interactions in genetically engineered cells
WO2016205749A1 (en) 2015-06-18 2016-12-22 The Broad Institute Inc. Novel crispr enzymes and systems
JP7033453B2 (ja) 2015-06-30 2022-03-10 セレクティス 特異的エンドヌクレアーゼを使用した遺伝子不活化によってｎｋ細胞の機能性を改善する方法
AU2016291778B2 (en) * 2015-07-13 2021-05-06 Sangamo Therapeutics, Inc. Delivery methods and compositions for nuclease-mediated genome engineering
US20170014449A1 (en) * 2015-07-13 2017-01-19 Elwha LLC, a limited liability company of the State of Delaware Site-specific epigenetic editing
HK1255161A1 (zh) * 2015-07-15 2019-08-09 Juno Therapeutics, Inc. 用於过继性细胞治疗的工程细胞
US11474085B2 (en) 2015-07-28 2022-10-18 Flodesign Sonics, Inc. Expanded bed affinity selection
US11459540B2 (en) 2015-07-28 2022-10-04 Flodesign Sonics, Inc. Expanded bed affinity selection
GB2592821B (en) 2015-07-31 2022-01-12 Univ Minnesota Modified cells and methods of therapy
WO2017025323A1 (en) 2015-08-11 2017-02-16 Cellectis Cells for immunotherapy engineered for targeting cd38 antigen and for cd38 gene inactivation
CN108348551A (zh) * 2015-08-28 2018-07-31 宾夕法尼亚大学董事会 表达嵌合细胞内信号传导分子的细胞的方法和组合物
EP3340995A4 (en) 2015-08-28 2019-04-03 The Trustees Of The University Of Pennsylvania METHOD AND COMPOSITIONS FOR CELLS FOR EXPRESSING A CHIMERIC INTRA-CELLULAR SIGNAL MOLECULE
EP3359660B1 (en) 2015-10-05 2019-12-04 Precision Biosciences, Inc. Engineered meganucleases with recognition sequences found in the human t cell receptor alpha constant region gene
JP6816133B2 (ja) * 2015-10-05 2021-01-20 プレシジョン バイオサイエンシズ，インク． 改変ヒトｔ細胞受容体アルファ定常領域遺伝子を含む遺伝子改変細胞
US12241053B2 (en) 2015-10-09 2025-03-04 The Brigham And Women's Hospital, Inc. Modulation of novel immune checkpoint targets
WO2017070429A1 (en) * 2015-10-22 2017-04-27 Regents Of The University Of Minnesota Methods involving editing polynucleotides that encode t cell receptor
IL310721B2 (en) 2015-10-23 2025-11-01 Harvard College Nucleobase editors and uses thereof
WO2017075451A1 (en) 2015-10-28 2017-05-04 The Broad Institute Inc. Compositions and methods for evaluating and modulating immune responses by detecting and targeting pou2af1
WO2017075478A2 (en) 2015-10-28 2017-05-04 The Broad Institute Inc. Compositions and methods for evaluating and modulating immune responses by use of immune cell gene signatures
WO2017075465A1 (en) 2015-10-28 2017-05-04 The Broad Institute Inc. Compositions and methods for evaluating and modulating immune responses by detecting and targeting gata3
CN108289913A (zh) 2015-10-30 2018-07-17 儿童国家医疗中心 从未致敏t细胞群体产生hpv抗原特异性t细胞
KR20250141836A (ko) 2015-11-04 2025-09-29 페이트 세러퓨틱스, 인코포레이티드 만능 세포의 유전자 조작
SG11201803145RA (en) 2015-11-04 2018-05-30 Fate Therapeutics Inc Methods and compositions for inducing hematopoietic cell differentiation
EP3370514A4 (en) * 2015-11-05 2019-03-27 Baylor College of Medicine EFFICIENT SCALABLE XENOTRANAPLANT SYSTEM FROM ONE PATIENT BASED ON A CHICKEN CHORIOAL ANTI-TEMEMBRBRANE (CAM) IN VIVO MODEL
AU2016355178B9 (en) 2015-11-19 2019-05-30 Massachusetts Institute Of Technology Lymphocyte antigen CD5-like (CD5L)-interleukin 12B (p40) heterodimers in immunity
WO2017093969A1 (en) 2015-12-04 2017-06-08 Novartis Ag Compositions and methods for immunooncology
EP3389677B1 (en) * 2015-12-18 2024-06-26 Sangamo Therapeutics, Inc. Targeted disruption of the t cell receptor
CN105505869A (zh) * 2015-12-21 2016-04-20 河南大学淮河医院 一种针对肿瘤干细胞的嵌合抗原受体t细胞
EP3184548A1 (en) * 2015-12-23 2017-06-28 Miltenyi Biotec GmbH Chimeric antigen receptor with cytokine receptor activating or blocking domain
IL299616A (en) 2016-01-08 2023-03-01 Univ California Conditionally active heterodimeric polypeptides and methods of using them
GB201604213D0 (en) * 2016-03-11 2016-04-27 Proximagen Ltd Drug combination and its use in therapy
JP2019509738A (ja) * 2016-03-11 2019-04-11 ブルーバード バイオ， インコーポレイテッド ゲノム編集された免疫エフェクター細胞
US20190161530A1 (en) * 2016-04-07 2019-05-30 Bluebird Bio, Inc. Chimeric antigen receptor t cell compositions
EP3439675A4 (en) 2016-04-08 2019-12-18 Purdue Research Foundation METHOD AND COMPOSITIONS FOR CAR-T CELL THERAPY
US11446398B2 (en) 2016-04-11 2022-09-20 Obsidian Therapeutics, Inc. Regulated biocircuit systems
CA3021634A1 (en) * 2016-04-15 2017-10-19 Zymeworks Inc. Multi-specific antigen-binding constructs targeting immunotherapeutics
EP4628587A3 (en) 2016-04-15 2026-02-25 Memorial Sloan Kettering Cancer Center Transgenic t cell and chimeric antigen receptor t cell compositions and related methods
WO2017178586A1 (en) 2016-04-15 2017-10-19 Cellectis A method of engineering prodrug-specific hypersensitive t-cells for immunotherapy by gene expression
WO2017178585A1 (en) 2016-04-15 2017-10-19 Cellectis A method of engineering drug-specific hypersensitive t-cells for immunotherapy by gene inactivation
AU2017254477A1 (en) 2016-04-18 2018-11-01 Jennifer G. ABELIN Improved HLA epitope prediction
WO2017192536A1 (en) 2016-05-02 2017-11-09 University Of Kansas Eliminating mhc restriction from the t cell receptor as a strategy for immunotherapy
US11214789B2 (en) 2016-05-03 2022-01-04 Flodesign Sonics, Inc. Concentration and washing of particles with acoustics
US11085035B2 (en) 2016-05-03 2021-08-10 Flodesign Sonics, Inc. Therapeutic cell washing, concentration, and separation utilizing acoustophoresis
AU2017280353B2 (en) 2016-06-24 2021-11-11 Inscripta, Inc. Methods for generating barcoded combinatorial libraries
AU2017291851B2 (en) * 2016-07-06 2022-10-13 Cellectis Sequential gene editing in primary immune cells
US11384156B2 (en) 2016-07-25 2022-07-12 The Nemours Foundation Adoptive T-cell therapy using EMPD-specific chimeric antigen receptors for treating IgE-mediated allergic diseases
CA3032498A1 (en) 2016-08-02 2018-02-08 TCR2 Therapeutics Inc. Compositions and methods for tcr reprogramming using fusion proteins
KR102546839B1 (ko) 2016-08-03 2023-06-23 워싱턴 유니버시티 키메라 항원 수용체를 이용한 t 세포 악성종양의 치료를 위한 car-t 세포의 유전자 편집
CN110214183A (zh) 2016-08-03 2019-09-06 哈佛大学的校长及成员们 腺苷核碱基编辑器及其用途
WO2018031683A1 (en) 2016-08-09 2018-02-15 President And Fellows Of Harvard College Programmable cas9-recombinase fusion proteins and uses thereof
WO2018035364A1 (en) 2016-08-17 2018-02-22 The Broad Institute Inc. Product and methods useful for modulating and evaluating immune responses
EP3995574A1 (en) 2016-08-24 2022-05-11 Sangamo Therapeutics, Inc. Regulation of gene expression using engineered nucleases
US11542509B2 (en) 2016-08-24 2023-01-03 President And Fellows Of Harvard College Incorporation of unnatural amino acids into proteins using base editing
KR102455249B1 (ko) * 2016-08-24 2022-10-17 상가모 테라퓨틱스, 인코포레이티드 가공된 표적 특이적 뉴클레아제
ES2981703T3 (es) 2016-09-02 2024-10-10 Lentigen Tech Inc Composiciones y métodos para tratar cáncer con DuoCars
WO2018049025A2 (en) 2016-09-07 2018-03-15 The Broad Institute Inc. Compositions and methods for evaluating and modulating immune responses
MA46236A (fr) 2016-09-14 2019-07-24 Janssen Biotech Inc Récepteurs antigéniques chimériques comprenant des domaines de la fibronectine de type iii spécifiques du bcma, et utilisations correspondantes
US12499971B2 (en) 2016-09-28 2025-12-16 The Broad Institute, Inc. Systematic screening and mapping of regulatory elements in non-coding genomic regions, methods, compositions, and applications thereof
MX2019003768A (es) 2016-10-03 2019-06-24 Juno Therapeutics Inc Moleculas de enlace especificas de hpv.
JP7248571B2 (ja) 2016-10-05 2023-03-29 フジフィルム セルラー ダイナミクス，インコーポレイテッド ＭｅＣＰ２が破壊された誘導多能性幹細胞からの成熟系列の生成
WO2018067993A1 (en) 2016-10-07 2018-04-12 TCR2 Therapeutics Inc. Compositions and methods for t-cell receptors reprogramming using fusion proteins
US12447213B2 (en) 2016-10-07 2025-10-21 The Broad Institute, Inc. Modulation of novel immune checkpoint targets
US11591582B2 (en) 2016-10-11 2023-02-28 2Seventy Bio, Inc. TCRα homing endonuclease variants
KR102622411B1 (ko) 2016-10-14 2024-01-10 프레지던트 앤드 펠로우즈 오브 하바드 칼리지 핵염기 에디터의 aav 전달
CN110520530A (zh) 2016-10-18 2019-11-29 明尼苏达大学董事会 肿瘤浸润性淋巴细胞和治疗方法
WO2018073394A1 (en) 2016-10-19 2018-04-26 Cellectis Cell death inducing chimeric antigen receptors
WO2018073391A1 (en) 2016-10-19 2018-04-26 Cellectis Targeted gene insertion for improved immune cells therapy
WO2018073393A2 (en) 2016-10-19 2018-04-26 Cellectis Tal-effector nuclease (talen) -modified allogenic cells suitable for therapy
US11873511B2 (en) * 2016-10-19 2024-01-16 Cellectis Targeted gene insertion for improved immune cells therapy
EP3529265A2 (en) * 2016-10-19 2019-08-28 Cellectis Tal-effector nuclease (talen) -modified allogenic cells suitable for therapy
WO2018075830A1 (en) 2016-10-19 2018-04-26 Flodesign Sonics, Inc. Affinity cell extraction by acoustics
EP3538550A1 (en) 2016-11-10 2019-09-18 Deutsches Krebsforschungszentrum Stiftung des Öffentlichen Rechts Or10h1 modulators and uses thereof
EP3321280B8 (en) 2016-11-10 2021-03-10 Deutsches Krebsforschungszentrum Stiftung des Öffentlichen Rechts Immune modulators for reducing immune-resistance in melanoma and other proliferative diseases
WO2018089386A1 (en) 2016-11-11 2018-05-17 The Broad Institute, Inc. Modulation of intestinal epithelial cell differentiation, maintenance and/or function through t cell action
JP7291396B2 (ja) 2016-11-22 2023-06-15 ティーシーアール２ セラピューティクス インク． 融合タンパク質を用いたｔｃｒの再プログラミングのための組成物及び方法
US11793833B2 (en) 2016-12-02 2023-10-24 Juno Therapeutics, Inc. Engineered B cells and related compositions and methods
EP3548055A4 (en) 2016-12-02 2020-08-19 University of Southern California SYNTHETIC IMMUNE RECEPTORS AND THEIR PROCESSES FOR USE
WO2018115189A1 (en) 2016-12-21 2018-06-28 Cellectis Stably enginereed proteasome inhibitor resistant immune cells for immunotherapy
WO2018119359A1 (en) 2016-12-23 2018-06-28 President And Fellows Of Harvard College Editing of ccr5 receptor gene to protect against hiv infection
CA3048211A1 (en) 2016-12-23 2018-06-28 Macrogenics, Inc. Adam9-binding molecules, and methods of use thereof
WO2018132479A1 (en) * 2017-01-10 2018-07-19 The General Hospital Corporation Modified t cells and methods of their use
US11549149B2 (en) 2017-01-24 2023-01-10 The Broad Institute, Inc. Compositions and methods for detecting a mutant variant of a polynucleotide
TW201839136A (zh) 2017-02-06 2018-11-01 瑞士商諾華公司 治療血色素異常症之組合物及方法
US11649288B2 (en) 2017-02-07 2023-05-16 Seattle Children's Hospital Phospholipid ether (PLE) CAR T cell tumor targeting (CTCT) agents
CN108395482B (zh) 2017-02-08 2021-02-05 西比曼生物科技（香港）有限公司 一种靶向cd20抗原嵌合抗原受体的构建及其工程化t细胞的活性鉴定
EP3583203B1 (en) * 2017-02-15 2023-11-01 2seventy bio, Inc. Donor repair templates multiplex genome editing
WO2018160622A1 (en) 2017-02-28 2018-09-07 Endocyte, Inc. Compositions and methods for car t cell therapy
EP3592853A1 (en) 2017-03-09 2020-01-15 President and Fellows of Harvard College Suppression of pain by gene editing
US12390514B2 (en) 2017-03-09 2025-08-19 President And Fellows Of Harvard College Cancer vaccine
US11542496B2 (en) 2017-03-10 2023-01-03 President And Fellows Of Harvard College Cytosine to guanine base editor
KR20230166145A (ko) 2017-03-15 2023-12-06 옥스포드 바이오메디카(유케이) 리미티드 방법
WO2018175636A2 (en) 2017-03-22 2018-09-27 Novartis Ag Compositions and methods for immunooncology
KR20240116572A (ko) 2017-03-23 2024-07-29 프레지던트 앤드 펠로우즈 오브 하바드 칼리지 핵산 프로그램가능한 dna 결합 단백질을 포함하는 핵염기 편집제
AU2018246377B2 (en) 2017-03-31 2025-01-30 Cellectis Sa Universal anti-CD22 chimeric antigen receptor engineered immune cells
US11963966B2 (en) 2017-03-31 2024-04-23 Dana-Farber Cancer Institute, Inc. Compositions and methods for treating ovarian tumors
WO2018183921A1 (en) 2017-04-01 2018-10-04 The Broad Institute, Inc. Methods and compositions for detecting and modulating an immunotherapy resistance gene signature in cancer
CA3058807A1 (en) 2017-04-03 2018-10-11 Biontech Us Inc. Protein antigens and uses thereof
US12590288B2 (en) 2017-04-12 2026-03-31 The Broad Institute, Inc. Method of treating an inflammatory disease by administering an agent which binds a surface receptor on a tuft cell that induces an ILC class 2 inflammatory response
EP3610266A4 (en) 2017-04-12 2021-04-21 Massachusetts Eye and Ear Infirmary TUMOR SIGNATURE OF METASTASIS, COMPOSITIONS OF SUBSTANCES AND USES THEREOF
WO2018189360A1 (en) 2017-04-13 2018-10-18 Cellectis New sequence specific reagents targeting ccr5 in primary hematopoietic cells
EP3612210A4 (en) * 2017-04-19 2021-01-27 Board Of Regents, The University Of Texas System MANIPULATED ANTIGEN RECEPTORS EXPRESSING IMMUNE CELLS
EP3391907B8 (en) 2017-04-20 2020-03-04 iOmx Therapeutics AG Intracellular kinase sik3 associated with resistance against anti-tumour immune responses, and uses thereof
EP3622092A4 (en) 2017-05-11 2021-06-23 The Broad Institute, Inc. METHODS AND COMPOSITIONS OF USE OF CD8 + TUMOR-INFILTRATING LYMPHOCYTE SUBTYPES AND GENE SIGNATURES THEREOF
US11560566B2 (en) 2017-05-12 2023-01-24 President And Fellows Of Harvard College Aptazyme-embedded guide RNAs for use with CRISPR-Cas9 in genome editing and transcriptional activation
MX2019013514A (es) 2017-05-12 2020-01-20 Crispr Therapeutics Ag Materiales y metodos para modificar celulas por ingenieria genetica y usos de los mismos en inmunooncologia.
US11166985B2 (en) 2017-05-12 2021-11-09 Crispr Therapeutics Ag Materials and methods for engineering cells and uses thereof in immuno-oncology
WO2018213726A1 (en) 2017-05-18 2018-11-22 The Broad Institute, Inc. Systems, methods, and compositions for targeted nucleic acid editing
WO2018231759A1 (en) * 2017-06-12 2018-12-20 Obsidian Therapeutics, Inc. Pde5 compositions and methods for immunotherapy
WO2018232195A1 (en) 2017-06-14 2018-12-20 The Broad Institute, Inc. Compositions and methods targeting complement component 3 for inhibiting tumor growth
US20210139870A1 (en) 2017-06-19 2021-05-13 Cellectis Anti-hbv combination therapies involving specific endonucleases
BR112019027133B8 (pt) 2017-06-20 2022-08-09 Inst Curie Uso de uma célula imune modificada deficiente para suv39h1
CA3068286A1 (en) * 2017-06-22 2018-12-27 Board Of Regents, The University Of Texas System Methods for producing regulatory immune cells and uses thereof
US10011849B1 (en) 2017-06-23 2018-07-03 Inscripta, Inc. Nucleic acid-guided nucleases
US9982279B1 (en) 2017-06-23 2018-05-29 Inscripta, Inc. Nucleic acid-guided nucleases
CA3067914A1 (en) 2017-06-30 2019-01-03 Cellectis Cellular immunotherapy for repetitive administration
EP3645038B1 (en) 2017-06-30 2026-02-18 Precision Biosciences, Inc. Genetically-modified t cells comprising a modified intron in the t cell receptor alpha gene
EP3645021A4 (en) 2017-06-30 2021-04-21 Intima Bioscience, Inc. ADENO-ASSOCIATED VIRAL VECTORS FOR GENE THERAPY
GB201710973D0 (en) 2017-07-07 2017-08-23 Avacta Life Sciences Ltd Scaffold proteins
US12049643B2 (en) 2017-07-14 2024-07-30 The Broad Institute, Inc. Methods and compositions for modulating cytotoxic lymphocyte activity
US20210130817A1 (en) 2017-07-14 2021-05-06 Cure Genetics Co., Ltd. Gene Editing System and Gene Editing Method
EP3655026A4 (en) 2017-07-17 2021-07-28 Janssen Biotech, Inc. ANTIGBINDING REGIONS AGAINST FIBRONECTIN TYPE III DOMAINS AND METHOD OF USING THEREOF
EP3638260A1 (en) 2017-07-21 2020-04-22 Cellectis Engineered immune cells resistant to tumor microoenvironment
WO2019016360A1 (en) 2017-07-21 2019-01-24 Cellectis MODIFIED IMMUNE CELLS RESISTANT TO TUMOR MICRO-ENVIRONMENT
CA3070998A1 (en) * 2017-07-25 2019-01-31 Board Of Regents, The University Of Texas System Enhanced chimeric antigen receptors and use thereof
WO2019020733A1 (en) 2017-07-26 2019-01-31 Cellectis METHODS OF IMMUNE CELL SELECTION OF THE ANTIGEN-DEPENDENT CHIMERIC ANTIGENIC RECEPTOR (CAR)
CN111801345A (zh) 2017-07-28 2020-10-20 哈佛大学的校长及成员们 使用噬菌体辅助连续进化(pace)的进化碱基编辑器的方法和组合物
EP3676376B1 (en) 2017-08-30 2025-01-15 President and Fellows of Harvard College High efficiency base editors comprising gam
KR20260026092A (ko) 2017-09-19 2026-02-25 메사추세츠 인스티튜트 오브 테크놀로지 키메라 항원 수용체 t 세포 요법을 위한 조성물 및 그의 용도
AU2018338318B2 (en) 2017-09-21 2022-12-22 Massachusetts Institute Of Technology Systems, methods, and compositions for targeted nucleic acid editing
WO2019070755A1 (en) 2017-10-02 2019-04-11 The Broad Institute, Inc. METHODS AND COMPOSITIONS FOR DETECTING AND MODULATING A GENETIC SIGNATURE OF IMMUNOTHERAPY RESISTANCE IN CANCER
JP2020537515A (ja) 2017-10-03 2020-12-24 ジュノー セラピューティクス インコーポレイテッド Ｈｐｖ特異的結合分子
WO2019072824A1 (en) 2017-10-09 2019-04-18 Cellectis IMPROVED ANTI-CD123 CAR IN UNIVERSAL MODIFIED IMMUNE T LYMPHOCYTES
KR20250107288A (ko) 2017-10-16 2025-07-11 더 브로드 인스티튜트, 인코퍼레이티드 아데노신 염기 편집제의 용도
KR20200075851A (ko) 2017-10-19 2020-06-26 셀렉티스 개선된 면역 세포들 치료를 위한 nk 억제제들의 타겟인 유전자 통합
MY204419A (en) 2017-10-31 2024-08-28 Servier Lab Methods and compositions for dosing of allogeneic chimeric antigen receptor t cells
WO2019094955A1 (en) 2017-11-13 2019-05-16 The Broad Institute, Inc. Methods and compositions for targeting developmental and oncogenic programs in h3k27m gliomas
EP3710039A4 (en) 2017-11-13 2021-08-04 The Broad Institute, Inc. METHODS AND COMPOSITIONS FOR TREATMENT OF CANCER BY TARGETING THE CLEC2D-KLRB1 PATH
CR20200251A (es) 2017-11-17 2020-07-17 Iovance Biotherapeutics Inc Expansión de til de aspirados con aguja fina y biopsias por punción
EP3714041A1 (en) 2017-11-22 2020-09-30 Iovance Biotherapeutics, Inc. Expansion of peripheral blood lymphocytes (pbls) from peripheral blood
WO2019106163A1 (en) 2017-12-01 2019-06-06 Cellectis Reprogramming of genetically engineered primary immune cells
KR102439221B1 (ko) 2017-12-14 2022-09-01 프로디자인 소닉스, 인크. 음향 트랜스듀서 구동기 및 제어기
US12406749B2 (en) 2017-12-15 2025-09-02 The Broad Institute, Inc. Systems and methods for predicting repair outcomes in genetic engineering
TW201930340A (zh) 2017-12-18 2019-08-01 美商尼恩醫療公司 新抗原及其用途
IL316257A (en) 2017-12-22 2024-12-01 Fate Therapeutics Inc Enhanced immune effector cells and use thereof
US12570958B2 (en) * 2017-12-22 2026-03-10 Cell Design Labs, Inc. Single- and multi-chain chimeric antigen receptors
WO2019119822A1 (en) * 2017-12-23 2019-06-27 Uwell Biopharma Inc. Pharmaceutical chimeric receptor composition and method thereof
EP3684399A1 (en) 2017-12-29 2020-07-29 Cellectis Method for improving production of car t cells
WO2019129850A1 (en) 2017-12-29 2019-07-04 Cellectis Off-the-shelf engineered cells for therapy
US11994512B2 (en) 2018-01-04 2024-05-28 Massachusetts Institute Of Technology Single-cell genomic methods to generate ex vivo cell systems that recapitulate in vivo biology with improved fidelity
EP3737743A1 (en) 2018-01-08 2020-11-18 Iovance Biotherapeutics, Inc. Processes for generating til products enriched for tumor antigen-specific t-cells
WO2019136459A1 (en) 2018-01-08 2019-07-11 Iovance Biotherapeutics, Inc. Processes for generating til products enriched for tumor antigen-specific t-cells
EP3508499A1 (en) 2018-01-08 2019-07-10 iOmx Therapeutics AG Antibodies targeting, and other modulators of, an immunoglobulin gene associated with resistance against anti-tumour immune responses, and uses thereof
US11713446B2 (en) 2018-01-08 2023-08-01 Iovance Biotherapeutics, Inc. Processes for generating TIL products enriched for tumor antigen-specific T-cells
US11311576B2 (en) 2018-01-22 2022-04-26 Seattle Children's Hospital Methods of use for CAR T cells
US20230158070A1 (en) 2018-01-30 2023-05-25 Cellectis Combination comprising allogeneic immune cells deficient for an antigen present on both t-cells and pathological cells and therapeutic antibody against said antigen
US12312416B2 (en) 2018-02-06 2025-05-27 Seattle Children's Hospital Fluorescein-specific cars exhibiting optimal t cell function against FL-PLE labelled tumors
GB201801920D0 (en) * 2018-02-06 2018-03-21 Autolus Ltd Polypeptides and methods
WO2019157454A1 (en) 2018-02-11 2019-08-15 Memorial Sloan-Kettering Cancer Center Non-hla restricted t cell receptors and uses thereof
US12473336B2 (en) 2018-02-21 2025-11-18 Board Of Regents, The University Of Texas System Methods for activation and expansion of natural killer cells and uses thereof
AU2019225174B2 (en) 2018-02-23 2025-11-20 Endocyte, Inc. Sequencing method for CAR T cell therapy
MX2020009371A (es) * 2018-03-09 2021-01-08 Tcr2 Therapeutics Inc Composiciones y métodos para la reprogramación de tcr mediante el uso de proteínas de fusión.
US20210017248A1 (en) * 2018-03-16 2021-01-21 The Regents Of The University Of California Cellular signaling domain engineering in chimeric antigen receptor-modified regulatory t cells
KR102817092B1 (ko) 2018-03-29 2025-06-09 페이트 세러퓨틱스, 인코포레이티드 조작된 면역 효과기 세포 및 이의 용도
MA52207A (fr) 2018-04-05 2021-02-17 Editas Medicine Inc Lymphocytes t exprimant un récepteur recombinant, polynucléotides et procédés associés
EP3773908A1 (en) 2018-04-05 2021-02-17 Juno Therapeutics, Inc. T cell receptors and engineered cells expressing same
CA3094468A1 (en) 2018-04-05 2019-10-10 Juno Therapeutics, Inc. Methods of producing cells expressing a recombinant receptor and related compositions
US11786554B2 (en) 2018-04-12 2023-10-17 Precision Biosciences, Inc. Optimized engineered nucleases having specificity for the human T cell receptor alpha constant region gene
US11957695B2 (en) 2018-04-26 2024-04-16 The Broad Institute, Inc. Methods and compositions targeting glucocorticoid signaling for modulating immune responses
WO2019210131A1 (en) 2018-04-27 2019-10-31 Iovance Biotherapeutics, Inc. Closed process for expansion and gene editing of tumor infiltrating lymphocytes and uses of same in immunotherapy
MX2020012028A (es) 2018-05-11 2021-03-29 Crispr Therapeutics Ag Metodos y composiciones para tratar el cancer.
US12157760B2 (en) 2018-05-23 2024-12-03 The Broad Institute, Inc. Base editors and uses thereof
WO2019232542A2 (en) 2018-06-01 2019-12-05 Massachusetts Institute Of Technology Methods and compositions for detecting and modulating microenvironment gene signatures from the csf of metastasis patients
US12036240B2 (en) 2018-06-14 2024-07-16 The Broad Institute, Inc. Compositions and methods targeting complement component 3 for inhibiting tumor growth
MX2020014243A (es) 2018-06-19 2021-05-12 Biontech Us Inc Neoantigenos y usos de los mismos.
WO2020007593A1 (en) 2018-07-02 2020-01-09 Cellectis Chimeric antigen receptors (car)-expressing cells and combination treatment for immunotherapy of patients with relapse refractory adverse genetic risk aml
US12522807B2 (en) 2018-07-09 2026-01-13 The Broad Institute, Inc. RNA programmable epigenetic RNA modifiers and uses thereof
MD3823665T2 (ro) 2018-07-19 2024-05-31 Regeneron Pharma Receptori antigenci chimerici cu specificitate BCMA și utilizările acestora
US20220177524A1 (en) * 2018-07-26 2022-06-09 Nanjing Legend Biotech Co., Ltd. Nef-containing t cells and methods of producing thereof
WO2020068304A2 (en) 2018-08-20 2020-04-02 The Broad Institute, Inc. Inhibitors of rna-guided nuclease target binding and uses thereof
WO2020041384A1 (en) 2018-08-20 2020-02-27 The Broad Institute, Inc. 3-phenyl-2-cyano-azetidine derivatives, inhibitors of rna-guided nuclease activity
US20210324357A1 (en) 2018-08-20 2021-10-21 The Brigham And Women's Hospital, Inc. Degradation domain modifications for spatio-temporal control of rna-guided nucleases
CA3111087A1 (en) 2018-08-29 2020-03-05 Nanjing Legend Biotech Co., Ltd. Anti-mesothelin chimeric antigen receptor (car) constructs and uses thereof
AU2019346335B2 (en) 2018-09-28 2024-07-25 Massachusetts Institute Of Technology Collagen-localized immunomodulatory molecules and methods thereof
WO2020072700A1 (en) 2018-10-02 2020-04-09 Dana-Farber Cancer Institute, Inc. Hla single allele lines
US20210379057A1 (en) 2018-10-16 2021-12-09 Massachusetts Institute Of Technology Nutlin-3a for use in treating a mycobacterium tuberculosis infection
WO2020092453A1 (en) 2018-10-29 2020-05-07 The Broad Institute, Inc. Nucleobase editors comprising geocas9 and uses thereof
MY210603A (en) 2018-11-05 2025-10-01 Iovance Biotherapeutics Inc Processes for production of tumor infiltrating lymphocytes and uses of the same in immunotherapy
WO2020096927A1 (en) 2018-11-05 2020-05-14 Iovance Biotherapeutics, Inc. Expansion of tils utilizing akt pathway inhibitors
JP7854297B2 (ja) 2018-11-05 2026-05-01 アイオバンス バイオセラピューティクス，インコーポレイテッド 改良された腫瘍反応性ｔ細胞の選択
US12611427B2 (en) 2018-11-05 2026-04-28 Iovance Biotherapeutics, Inc. Treatment of NSCLC patients refractory for anti-PD-1 antibody
WO2020097193A1 (en) 2018-11-06 2020-05-14 The Regents Of The University Of California Chimeric antigen receptors for phagocytosis
WO2020099572A1 (en) * 2018-11-14 2020-05-22 Fundación Pública Andaluza Progreso Y Salud Polynucleotide for safer and more effective immunotherapies
MX2021006208A (es) 2018-11-28 2021-10-01 Univ Texas Edición por multiplexación del genoma de células inmunitarias para mejorar la funcionalidad y resistencia al entorno supresor.
MX2021006393A (es) 2018-11-29 2021-10-13 Univ Texas Metodos para expansion ex vivo de celulas exterminadoras naturales y uso de las mismas.
US20200268797A1 (en) 2018-11-30 2020-08-27 Janssen Biotech, Inc. Gamma delta t cells and uses thereof
MX2021006194A (es) 2018-12-02 2021-06-30 Fate Therapeutics Inc Inmunoterapias mediante el uso de celulas efectoras potenciadas derivadas de ipsc.
US20220062394A1 (en) 2018-12-17 2022-03-03 The Broad Institute, Inc. Methods for identifying neoantigens
CA3123392A1 (en) 2018-12-19 2020-06-25 Iovance Biotherapeutics, Inc. Methods of expanding tumor infiltrating lymphocytes using engineered cytokine receptor pairs and uses thereof
US11739156B2 (en) 2019-01-06 2023-08-29 The Broad Institute, Inc. Massachusetts Institute of Technology Methods and compositions for overcoming immunosuppression
US12351837B2 (en) 2019-01-23 2025-07-08 The Broad Institute, Inc. Supernegatively charged proteins and uses thereof
WO2020180733A1 (en) 2019-03-01 2020-09-10 Iovance Biotherapeutics, Inc. Expansion of tumor infiltrating lymphocytes from liquid tumors and therapeutic uses thereof
US20220154282A1 (en) 2019-03-12 2022-05-19 The Broad Institute, Inc. Detection means, compositions and methods for modulating synovial sarcoma cells
EP3942023A1 (en) 2019-03-18 2022-01-26 The Broad Institute, Inc. Compositions and methods for modulating metabolic regulators of t cell pathogenicity
WO2020191233A1 (en) 2019-03-19 2020-09-24 The Broad Institute, Inc. Methods and compositions for editing nucleotide sequences
WO2020191378A1 (en) 2019-03-21 2020-09-24 Allogene Therapeutics, Inc. METHODS FOR ENHANCING TCRαβ+ CELL DEPLETION EFFICIENCY
KR102691932B1 (ko) 2019-04-03 2024-08-06 프리시젼 바이오사이언시스 인코포레이티드 마이크로RNA-적응 shRNA(shRNAmiR)를 포함하는 유전자-변형 면역 세포
KR20210152536A (ko) 2019-04-12 2021-12-15 더 보드 오브 리젠츠 오브 더 유니버시티 오브 텍사스 시스템 조절 b 세포의 생산 방법 및 이의 용도
US12473543B2 (en) 2019-04-17 2025-11-18 The Broad Institute, Inc. Adenine base editors with reduced off-target effects
SG11202111031RA (en) * 2019-04-26 2021-11-29 Allogene Therapeutics Inc Rituximab-resistant chimeric antigen receptors and uses thereof
MX2021013359A (es) 2019-04-30 2022-01-31 Crispr Therapeutics Ag Terapia de celulas alogénicas de neoplasias malignas de células b usando células t modificadas genéticamente dirigidas a cd19.
US11026973B2 (en) 2019-04-30 2021-06-08 Myeloid Therapeutics, Inc. Engineered phagocytic receptor compositions and methods of use thereof
EP3736330A1 (en) 2019-05-08 2020-11-11 European Molecular Biology Laboratory Modified adeno-associated virus (aav) particles for gene therapy
WO2020232029A1 (en) 2019-05-13 2020-11-19 Iovance Biotherapeutics, Inc. Methods and compositions for selecting tumor infiltrating lymphocytes and uses of the same in immunotherapy
US20220235340A1 (en) 2019-05-20 2022-07-28 The Broad Institute, Inc. Novel crispr-cas systems and uses thereof
US20220226464A1 (en) 2019-05-28 2022-07-21 Massachusetts Institute Of Technology Methods and compositions for modulating immune responses
JP7644722B2 (ja) * 2019-06-01 2025-03-12 シベック バイオテクノロジーズ，インコーポレイティド 真核細胞への遺伝子編集システムの送達のための細菌プラットフォーム
WO2020263399A1 (en) 2019-06-26 2020-12-30 Massachusetts Institute Of Technology Immunomodulatory fusion protein-metal hydroxide complexes and methods thereof
KR20220051164A (ko) 2019-07-05 2022-04-26 아이오엠엑스 테라퓨틱스 아게 Igsf11 (vsig3)의 항체 결합 igc2 및 이의 용도
CN114258429A (zh) 2019-07-17 2022-03-29 菲特治疗公司 免疫效应细胞工程化和其用途
BR112022001148A2 (pt) 2019-07-23 2022-03-15 Inst Nat Sante Rech Med Células imunes modificadas, composição farmacêutica, kit, uso de uma célula imune modificada e invenção de produto
EP4004049A1 (en) 2019-07-24 2022-06-01 Regeneron Pharmaceuticals, Inc. Chimeric antigen receptors with mage-a4 specificity and uses thereof
WO2021030627A1 (en) 2019-08-13 2021-02-18 The General Hospital Corporation Methods for predicting outcomes of checkpoint inhibition and treatment thereof
US12421557B2 (en) 2019-08-16 2025-09-23 The Broad Institute, Inc. Methods for predicting outcomes and treating colorectal cancer using a cell atlas
CA3148179A1 (en) * 2019-08-20 2021-02-25 Bruce J. Mccreedy Jr. Lymphodepletion dosing regimens for cellular immunotherapies
US20220305056A1 (en) 2019-08-27 2022-09-29 Janssen Biotech, Inc. Chimeric antigen receptor system and uses thereof
WO2021041922A1 (en) 2019-08-30 2021-03-04 The Broad Institute, Inc. Crispr-associated mu transposase systems
CN114981409A (zh) 2019-09-03 2022-08-30 美洛德生物医药公司 用于基因组整合的方法和组合物
WO2021050789A1 (en) 2019-09-10 2021-03-18 Obsidian Therapeutics, Inc. Ca2-il15 fusion proteins for tunable regulation
WO2021061648A1 (en) 2019-09-23 2021-04-01 Massachusetts Institute Of Technology Methods and compositions for stimulation of endogenous t cell responses
US12297426B2 (en) 2019-10-01 2025-05-13 The Broad Institute, Inc. DNA damage response signature guided rational design of CRISPR-based systems and therapies
US12394502B2 (en) 2019-10-02 2025-08-19 The General Hospital Corporation Method for predicting HLA-binding peptides using protein structural features
US12195725B2 (en) 2019-10-03 2025-01-14 Dana-Farber Cancer Institute, Inc. Compositions and methods for modulating and detecting tissue specific TH17 cell pathogenicity
US11981922B2 (en) 2019-10-03 2024-05-14 Dana-Farber Cancer Institute, Inc. Methods and compositions for the modulation of cell interactions and signaling in the tumor microenvironment
US11793787B2 (en) 2019-10-07 2023-10-24 The Broad Institute, Inc. Methods and compositions for enhancing anti-tumor immunity by targeting steroidogenesis
US12435330B2 (en) 2019-10-10 2025-10-07 The Broad Institute, Inc. Methods and compositions for prime editing RNA
JP2023500799A (ja) 2019-10-18 2023-01-11 トラスティーズ オブ ボストン ユニバーシティ Ｃａｌ－ｔコンストラクトおよびその使用
EP4048295A1 (en) 2019-10-25 2022-08-31 Iovance Biotherapeutics, Inc. Gene editing of tumor infiltrating lymphocytes and uses of same in immunotherapy
US11844800B2 (en) 2019-10-30 2023-12-19 Massachusetts Institute Of Technology Methods and compositions for predicting and preventing relapse of acute lymphoblastic leukemia
CA3162755A1 (en) * 2019-11-25 2021-06-03 Kyoto University T-cell master cell bank
JP2023504081A (ja) * 2019-11-27 2023-02-01 ボード オブ リージェンツ，ザ ユニバーシティ オブ テキサス システム 神経膠芽細胞腫及び他の癌を処置するためのナチュラルキラー細胞免疫療法
WO2021119538A1 (en) * 2019-12-11 2021-06-17 Myeloid Therapeutics, Inc. Therapeutic cell compositions and methods for manufacture and uses thereof
US12516291B2 (en) 2019-12-11 2026-01-06 Iovance Biotherapeutics, Inc. Processes for the production of tumor infiltrating lymphocytes (TILs) and methods of using the same
US10980836B1 (en) 2019-12-11 2021-04-20 Myeloid Therapeutics, Inc. Therapeutic cell compositions and methods of manufacturing and use thereof
EP4081537A1 (en) 2019-12-23 2022-11-02 Cellectis New mesothelin specific chimeric antigen receptors (car) for solid tumors cancer immunotherapy
US11865168B2 (en) 2019-12-30 2024-01-09 Massachusetts Institute Of Technology Compositions and methods for treating bacterial infections
KR20220141299A (ko) 2020-01-14 2022-10-19 신테카인, 인크. Il2 오르토로그 및 사용 방법
WO2021146641A1 (en) 2020-01-17 2021-07-22 The Broad Institute, Inc. Small type ii-d cas proteins and methods of use thereof
US12165747B2 (en) 2020-01-23 2024-12-10 The Broad Institute, Inc. Molecular spatial mapping of metastatic tumor microenvironment
CN115210252A (zh) 2020-02-04 2022-10-18 西雅图儿童医院（Dba西雅图儿童研究所） 抗二硝基苯酚的嵌合抗原受体
MX2022010340A (es) 2020-02-24 2022-09-19 Allogene Therapeutics Inc Celulas t con car de bcma con actividades mejoradas.
CN115552015A (zh) * 2020-02-28 2022-12-30 香港中文大学 经由同时敲入和基因破坏来改造免疫细胞
CN115485369A (zh) 2020-03-03 2022-12-16 詹森生物科技公司 γδT细胞及其用途
JP2023517063A (ja) 2020-03-10 2023-04-21 マサチューセッツ インスティテュート オブ テクノロジー 操作されたメモリー様ｎｋ細胞を作製するための方法およびその組成物
BR112022017924A2 (pt) 2020-03-10 2022-12-20 Massachusetts Inst Technology Composições e métodos para imunoterapia de câncer npm1c-positivo
CN113402612A (zh) 2020-03-17 2021-09-17 西比曼生物科技（香港）有限公司 靶向cd19和cd20的联合嵌合抗原受体及其应用
US20210340524A1 (en) 2020-05-01 2021-11-04 Massachusetts Institute Of Technology Methods for identifying chimeric antigen receptor-targeting ligands and uses thereof
US12433954B2 (en) 2020-05-01 2025-10-07 Massachusetts Institute Of Technology Methods of activating anti-CD19 chimeric antigen receptor (CAR) T cells using amphiphilic ligand conjugates comprising CAR-targeting protein sequence motifs
CA3176826A1 (en) 2020-05-04 2021-11-11 Iovance Biotherapeutics, Inc. Processes for production of tumor infiltrating lymphocytes and uses of the same in immunotherapy
CN115803435A (zh) 2020-05-06 2023-03-14 塞勒克提斯公司 用于在细胞基因组中靶向插入外源序列的方法
IL297761A (en) 2020-05-08 2022-12-01 Broad Inst Inc Methods and compositions for simultaneously editing two helices of a designated double-helix nucleotide sequence
EP3910331A1 (en) 2020-05-15 2021-11-17 iOmx Therapeutics AG Intracellular kinase associated with resistance against t-cell mediated cytotoxicity, and uses thereof
BR112022025806A2 (pt) 2020-06-19 2023-03-07 Fate Therapeutics Inc Combinação de tipos de células efetoras derivadas de ipsc para uso em imunoterapia
WO2022003158A1 (en) 2020-07-03 2022-01-06 Cellectis S.A. Method for determining potency of chimeric antigen receptor expressing immune cells
EP4175668A1 (en) 2020-07-06 2023-05-10 iOmx Therapeutics AG Antibodies binding igv of igsf11 (vsig3) and uses thereof
JP2023535371A (ja) 2020-07-17 2023-08-17 シミュレックス インコーポレイテッド 免疫抑制シグナル伝達をリダイレクトするためのキメラＭｙＤ８８受容体ならびに関連する組成物および方法
EP4185616A1 (en) 2020-07-24 2023-05-31 Cellectis S.A. T-cells expressing immune cell engagers in allogenic settings
EP4188395A1 (en) 2020-07-30 2023-06-07 Institut Curie Immune cells defective for socs1
CA3186325A1 (en) 2020-07-31 2022-02-03 Andre Choulika Dual car-t cells
US20220031751A1 (en) 2020-08-03 2022-02-03 Kyverna Therapeutics, Inc. Methods of producing t regulatory cells, methods of transducing t cells, and uses of the same
US20230321239A1 (en) 2020-08-14 2023-10-12 H. Lee Moffitt Cancer Center And Research Institute Inc. Chimeric antigen receptor t cells for treating autoimmunity
WO2022076606A1 (en) 2020-10-06 2022-04-14 Iovance Biotherapeutics, Inc. Treatment of nsclc patients with tumor infiltrating lymphocyte therapies
JP2023546359A (ja) 2020-10-06 2023-11-02 アイオバンス バイオセラピューティクス，インコーポレイテッド 腫瘍浸潤リンパ球療法によるｎｓｃｌｃ患者の治療
EP4240367A4 (en) 2020-11-04 2024-10-16 Myeloid Therapeutics, Inc. MODIFIED CHIMERIC FUSION PROTEIN COMPOSITIONS AND METHODS OF USE THEREOF
AU2021378075B2 (en) 2020-11-11 2025-03-27 Borea Therapeutics S.R.L. Modified viral particles for gene therapy
WO2022109277A1 (en) * 2020-11-20 2022-05-27 Pact Pharma, Inc. COMPOSITIONS AND METHODS FOR THE TREATMENT OF CANCER USING A TGFβRII ENGINEERED T CELL THERAPY
EP4251645A1 (en) 2020-11-25 2023-10-04 Catamaran Bio, Inc. Cellular therapeutics engineered with signal modulators and methods of use thereof
WO2022112596A1 (en) 2020-11-30 2022-06-02 Cellectis Sa Use of aminoquinoline compounds for higher gene integration
US11661459B2 (en) 2020-12-03 2023-05-30 Century Therapeutics, Inc. Artificial cell death polypeptide for chimeric antigen receptor and uses thereof
KR20230118887A (ko) 2020-12-03 2023-08-14 센츄리 쎄라퓨틱스 인코포레이티드 유전자 조작 세포 및 이의 용도
WO2022132720A1 (en) * 2020-12-14 2022-06-23 Allogene Therapeutics, Inc. Methods and reagents for characterizing car t cells for therapies
EP4262827A1 (en) 2020-12-17 2023-10-25 Iovance Biotherapeutics, Inc. Treatment of cancers with tumor infiltrating lymphocytes
AU2021401302A1 (en) 2020-12-17 2023-07-06 Iovance Biotherapeutics, Inc. Treatment with tumor infiltrating lymphocyte therapies in combination with ctla-4 and pd-1 inhibitors
AR124414A1 (es) 2020-12-18 2023-03-22 Century Therapeutics Inc Sistema de receptor de antígeno quimérico con especificidad de receptor adaptable
TW202342542A (zh) * 2020-12-23 2023-11-01 大陸商廣東菲鵬製藥股份有限公司 抗pd-l1抗體、編碼其的核酸、包含其的載體、細胞、藥物組合物及其用途
EP4271817A2 (en) 2020-12-30 2023-11-08 Alaunos Therapeutics, Inc. Recombinant vectors comprising polycistronic expression cassettes and methods of use thereof
AU2022205377A1 (en) 2021-01-08 2023-07-20 Cellanome, Inc. Devices and methods for analyzing biological samples
US12576400B2 (en) 2021-01-08 2026-03-17 Cellanome, Inc. Methods for incubating and analyzing a cell in a compartment of a fluidic device
WO2022165260A1 (en) 2021-01-29 2022-08-04 Iovance Biotherapeutics, Inc. Methods of making modified tumor infiltrating lymphocytes and their use in adoptive cell therapy
WO2022165419A1 (en) 2021-02-01 2022-08-04 Kyverna Therapeutics, Inc. Methods for increasing t-cell function
KR20230153529A (ko) * 2021-02-19 2023-11-06 프리트 엠. 쇼드하리 다양한 면역세포를 위한 단일사슬 및 다중사슬 합성 항원 수용체
WO2022197949A2 (en) 2021-03-17 2022-09-22 Myeloid Therapeutics, Inc. Engineered chimeric fusion protein compositions and methods of use thereof
US20240191191A1 (en) 2021-03-19 2024-06-13 Iovance Biotherapeutics, Inc. Methods for infiltrating lymphocyte (til) expansion related to cd39/cd69 selection and gene knockout in tils
CA3213080A1 (en) 2021-03-23 2022-09-29 Krit RITTHIPICHAI Cish gene editing of tumor infiltrating lymphocytes and uses of same in immunotherapy
JP2024512029A (ja) 2021-03-25 2024-03-18 アイオバンス バイオセラピューティクス，インコーポレイテッド Ｔ細胞共培養効力アッセイのための方法及び組成物、ならびに細胞療法製品との使用
CA3215830A1 (en) 2021-04-19 2022-10-27 Rafael CUBAS Chimeric costimulatory receptors, chemokine receptors, and the use of same in cellular immunotherapies
US20240197880A1 (en) 2021-04-30 2024-06-20 Cellectis S.A. New anti-muc1 cars and gene edited immune cells for solid tumors cancer immunotherapy
AU2022271212A1 (en) 2021-05-04 2023-11-30 Regeneron Pharmaceuticals, Inc. Chimeric antigen receptors with mage-a4 specificity and uses thereof
BR112023023642A2 (pt) 2021-05-11 2024-01-30 Myeloid Therapeutics Inc Métodos e composições para integração genômica
JP2024519029A (ja) 2021-05-17 2024-05-08 アイオバンス バイオセラピューティクス，インコーポレイテッド Ｐｄ－１遺伝子編集された腫瘍浸潤リンパ球及び免疫療法におけるその使用
AU2022277649A1 (en) 2021-05-21 2023-11-30 Cellectis S.A. Enhancing efficacy of t-cell-mediated immunotherapy by modulating cancer-associated fibroblasts in solid tumors
US20220409665A1 (en) 2021-06-15 2022-12-29 Allogene Therapeutics, Inc. Selective targeting of host cd70+ alloreactive cells to prolong allogeneic car t cell persistence
US20250288666A1 (en) 2021-07-14 2025-09-18 Synthekine, Inc. Methods and compositions for use in cell therapy of neoplastic disease
EP4373270A2 (en) 2021-07-22 2024-05-29 Iovance Biotherapeutics, Inc. Method for cryopreservation of solid tumor fragments
JP2024527961A (ja) 2021-07-28 2024-07-26 アイオバンス バイオセラピューティクス，インコーポレイテッド Ｋｒａｓ阻害剤と併用した腫瘍浸潤リンパ球療法によるがん患者の治療
AU2022318416A1 (en) 2021-07-29 2024-01-25 Takeda Pharmaceutical Company Limited Engineered immune cell that specifically targets mesothelin and uses thereof
IL310550A (en) 2021-08-04 2024-03-01 Univ Colorado Regents LAT-activating chimeric antigen receptor T cells and methods of using them
WO2023039488A1 (en) 2021-09-09 2023-03-16 Iovance Biotherapeutics, Inc. Processes for generating til products using pd-1 talen knockdown
WO2023077015A2 (en) 2021-10-27 2023-05-04 Iovance Biotherapeutics, Inc. Systems and methods for coordinating manufacturing of cells for patient-specific immunotherapy
US20260083848A1 (en) 2021-11-03 2026-03-26 Viracta Therapeutics, Inc. Combination of car t-cell therapy with btk inhibitors and methods of use thereof
WO2023081900A1 (en) 2021-11-08 2023-05-11 Juno Therapeutics, Inc. Engineered t cells expressing a recombinant t cell receptor (tcr) and related systems and methods
EP4437091A1 (en) 2021-11-23 2024-10-02 Cellectis SA New tale protein scaffolds with improved on-target/off-target activity ratios
JP2025501272A (ja) 2021-12-28 2025-01-17 ムネモ・セラピューティクス 不活性化されたｓｕｖ３９ｈ１及び改変ｔｃｒを有する免疫細胞
EP4460564A4 (en) * 2022-01-08 2026-02-11 Carogen Corp MULTI-ANTIGEN THERAPEUTIC VACCINES TO TREAT OR PREVENT CHRONIC HEPATITIS B VIRUS INFECTION
EP4469065A1 (en) 2022-01-28 2024-12-04 Iovance Biotherapeutics, Inc. Cytokine associated tumor infiltrating lymphocytes compositions and methods
EP4502177A4 (en) 2022-03-24 2026-03-18 Nanjing Legend Biotech Co Ltd METHOD FOR PREPARING A DNA BANK AND DETECTING A RETROVIRAL INTEGRATION SITE
WO2023196877A1 (en) 2022-04-06 2023-10-12 Iovance Biotherapeutics, Inc. Treatment of nsclc patients with tumor infiltrating lymphocyte therapies
US20250228943A1 (en) 2022-04-08 2025-07-17 Fate Therapeutics, Inc. Cells having solid tumor targeting backbone and use thereof
US20250222029A1 (en) 2022-04-08 2025-07-10 Fate Therapeutics, Inc. Chimeric antigen receptor for tumor targeting
JP2025512401A (ja) 2022-04-15 2025-04-17 アイオバンス バイオセラピューティクス，インコーポレイテッド 特定のサイトカインの組み合わせ及び／またはＡＫＴｉ処理を使用したＴＩＬ拡張プロセス
CA3251533A1 (en) 2022-05-10 2023-11-16 Iovance Biotherapeutics, Inc. TREATMENT OF CANCER PATIENTS WITH TUMOR-INFILTRATING LYMPHOCYTE THERAPIES IN COMBINATION WITH AN IL-15R AGONIST
EP4279085A1 (en) 2022-05-20 2023-11-22 Mnemo Therapeutics Compositions and methods for treating a refractory or relapsed cancer or a chronic infectious disease
WO2023233003A1 (en) 2022-06-03 2023-12-07 Cellectis Sa Tale base editors for gene and cell therapy
AU2023298102A1 (en) 2022-06-30 2024-11-14 Cellectis S.A. Enhancing safety of t-cell-mediated immunotherapy
WO2024022509A1 (en) * 2022-07-29 2024-02-01 Nanjing Legend Biotech Co., Ltd. Methods for promoting persistence of cell therapy
EP4583890A1 (en) 2022-09-09 2025-07-16 Iovance Biotherapeutics, Inc. Processes for generating til products using pd-1/tigit talen double knockdown
EP4583889A1 (en) 2022-09-09 2025-07-16 Iovance Biotherapeutics, Inc. Processes for generating til products using pd-1/tigit talen double knockdown
US20260091113A1 (en) * 2022-09-19 2026-04-02 Emendobio Inc. Biallelic Knockout of CTLA4
WO2024062138A1 (en) 2022-09-23 2024-03-28 Mnemo Therapeutics Immune cells comprising a modified suv39h1 gene
WO2024077256A1 (en) 2022-10-07 2024-04-11 The General Hospital Corporation Methods and compositions for high-throughput discovery ofpeptide-mhc targeting binding proteins
JP2025536578A (ja) 2022-11-03 2025-11-07 セレクティス ソシエテ アノニム Ｔ細胞媒介免疫療法の有効性及び安全性の増進
WO2024098024A1 (en) 2022-11-04 2024-05-10 Iovance Biotherapeutics, Inc. Expansion of tumor infiltrating lymphocytes from liquid tumors and therapeutic uses thereof
EP4612277A1 (en) 2022-11-04 2025-09-10 Iovance Biotherapeutics, Inc. Methods for tumor infiltrating lymphocyte (til) expansion related to cd39/cd103 selection
JP2025539712A (ja) 2022-11-21 2025-12-09 アイオバンス バイオセラピューティクス，インコーポレイテッド 遺伝子編集されたｔ細胞の増殖能を評価するための方法
JP2025539816A (ja) 2022-11-21 2025-12-09 アイオバンス バイオセラピューティクス，インコーポレイテッド 腫瘍浸潤リンパ球の増幅のための２次元プロセス及びそれからの治療法
WO2024118836A1 (en) 2022-11-30 2024-06-06 Iovance Biotherapeutics, Inc. Processes for production of tumor infiltrating lymphocytes with shortened rep step
WO2024124044A1 (en) 2022-12-07 2024-06-13 The Brigham And Women’S Hospital, Inc. Compositions and methods targeting sat1 for enhancing anti¬ tumor immunity during tumor progression
WO2024121385A1 (en) 2022-12-09 2024-06-13 Cellectis S.A. Two-dose regimen in immunotherapy
CN116284370B (zh) * 2023-02-27 2024-05-28 南京立顶医疗科技有限公司 一种多聚体糖化血红蛋白单克隆抗体及制备方法
WO2024246301A1 (en) 2023-06-02 2024-12-05 Cellectis Sa Methods for identifying tale base editors off-sites
CN121532650A (zh) 2023-06-20 2026-02-13 艾洛基治疗公司 工程化的细胞的检测方法
CN121889172A (zh) 2023-07-21 2026-04-17 意大利商博雷亚医疗有限责任公司 制备表面修饰病毒衣壳的方法
WO2025021772A1 (en) 2023-07-21 2025-01-30 Borea Therapeutics S.R.L. Chemogenetic surface modified viral particles
LU504827B1 (en) 2023-07-28 2025-01-28 Univ Saarland Compounds and compositions for use in the treatment of lung diseases
CN116987699B (zh) * 2023-09-05 2024-08-27 深圳市艾迪贝克生物医药有限公司 用于制备通用型car-t细胞的基因片段、其工具系统及应用
EP4520334A1 (en) 2023-09-07 2025-03-12 Mnemo Therapeutics Methods and compositions for improving immune response
WO2025054540A1 (en) 2023-09-08 2025-03-13 Iovance Biotherapeutics, Inc. Methods of gene-editing using programmable nucleases
WO2025059533A1 (en) 2023-09-13 2025-03-20 The Broad Institute, Inc. Crispr enzymes and systems
WO2025072571A1 (en) 2023-09-27 2025-04-03 Cellanome, Inc. Cell culture within microfluidic structures
CN117164714B (zh) * 2023-10-08 2024-04-23 北京奇迈永华生物科技有限公司 一种靶向bcma的抗体及其应用
WO2025097055A2 (en) 2023-11-02 2025-05-08 The Broad Institute, Inc. Compositions and methods of use of t cells in immunotherapy
WO2025101484A1 (en) 2023-11-06 2025-05-15 Iovance Biotherapeutics, Inc. Treatment of endometrial cancers with tumor infiltrating lymphocyte therapies
WO2025117544A1 (en) 2023-11-29 2025-06-05 The Broad Institute, Inc. Engineered omega guide molecule and iscb compositions, systems, and methods of use thereof
WO2025163107A1 (en) 2024-02-01 2025-08-07 Institut Gustave Roussy Immune cells defective for znf217 and uses thereof
WO2025171182A1 (en) 2024-02-08 2025-08-14 Iovance Biotherapeutics, Inc. Treatment of cancer patients with tumor infiltrating lymphocyte therapies in combination with cancer vaccine
WO2025196087A1 (en) 2024-03-19 2025-09-25 Borea Therapeutics S.R.L. Targeting tissues in the cns
CN118027211A (zh) * 2024-04-11 2024-05-14 上海惠盾因泰生物科技有限公司 一种识别重组egf-crm197疫苗的单克隆抗体及其应用
US20250345431A1 (en) 2024-05-10 2025-11-13 Juno Therapeutics, Inc. Genetically engineered t cells expressing a cd19 chimeric antigen receptor (car) and uses thereof for allogeneic cell therapy
WO2026046724A1 (en) 2024-08-30 2026-03-05 Cellectis Sa Tale protein scaffolds involving fusions of monopartite and bipartite nls
CN120058920B (zh) * 2025-04-29 2025-09-09 山东省农业科学院家禽研究所（山东省无特定病原鸡研究中心） 抗s11型鸭疫里默氏杆菌单克隆抗体及其阻断elisa抗体检测试剂盒和应用

Family Cites Families (104)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR901228A (fr) 1943-01-16 1945-07-20 Deutsche Edelstahlwerke Ag Système d'aimant à entrefer annulaire
US4474893A (en) 1981-07-01 1984-10-02 The University of Texas System Cancer Center Recombinant monoclonal antibodies
US4683195A (en) 1986-01-30 1987-07-28 Cetus Corporation Process for amplifying, detecting, and/or-cloning nucleic acid sequences
US6905680B2 (en) 1988-11-23 2005-06-14 Genetics Institute, Inc. Methods of treating HIV infected subjects
US5858358A (en) 1992-04-07 1999-01-12 The United States Of America As Represented By The Secretary Of The Navy Methods for selectively stimulating proliferation of T cells
US6534055B1 (en) 1988-11-23 2003-03-18 Genetics Institute, Inc. Methods for selectively stimulating proliferation of T cells
US6352694B1 (en) 1994-06-03 2002-03-05 Genetics Institute, Inc. Methods for inducing a population of T cells to proliferate using agents which recognize TCR/CD3 and ligands which stimulate an accessory molecule on the surface of the T cells
WO1992010591A1 (en) 1990-12-14 1992-06-25 Cell Genesys, Inc. Chimeric chains for receptor-associated signal transduction pathways
IL103418A (en) * 1991-10-15 1997-11-20 Wellcome Found Therapeutic agent for the t-cell mediated inflammation of the joints and its production
WO1993019163A1 (en) 1992-03-18 1993-09-30 Yeda Research And Development Co, Ltd. Chimeric receptor genes and cells transformed therewith
US6129914A (en) 1992-03-27 2000-10-10 Protein Design Labs, Inc. Bispecific antibody effective to treat B-cell lymphoma and cell line
US5556763A (en) * 1992-04-06 1996-09-17 United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Evaluation and treatment of patients with progressive immunosuppression
US5770396A (en) * 1992-04-16 1998-06-23 The United States Of America As Represented By The Department Of Health And Human Services Isolation characterization, and use of the human beta subunit of the high affinity receptor for immunoglobulin E
US7175843B2 (en) 1994-06-03 2007-02-13 Genetics Institute, Llc Methods for selectively stimulating proliferation of T cells
US5668263A (en) * 1994-12-16 1997-09-16 Smithkline Beecham Corporation Conserved yeast nucleic acid sequences
US7067318B2 (en) 1995-06-07 2006-06-27 The Regents Of The University Of Michigan Methods for transfecting T cells
US6692964B1 (en) 1995-05-04 2004-02-17 The United States Of America As Represented By The Secretary Of The Navy Methods for transfecting T cells
US6010613A (en) 1995-12-08 2000-01-04 Cyto Pulse Sciences, Inc. Method of treating materials with pulsed electrical fields
US5766944A (en) * 1996-12-31 1998-06-16 Ruiz; Margaret Eileen T cell differentiation of CD34+ stem cells in cultured thymic epithelial fragments
US6004779A (en) * 1997-08-22 1999-12-21 Scriptgen Pharmaceuticals, Inc. Regulated gene expression in yeast
HUP0203035A3 (en) * 1998-07-14 2007-12-28 Corixa Corp Compositions and methods for therapy and diagnosis of prostate cancer
US6673594B1 (en) * 1998-09-29 2004-01-06 Organ Recovery Systems Apparatus and method for maintaining and/or restoring viability of organs
JP2004500029A (ja) * 1999-06-30 2004-01-08 コリクサ　コーポレイション 肺癌の治療および診断のための組成物および方法
CA2397741A1 (en) * 2000-01-14 2001-07-19 Corixa Corporation Compositions and methods for the therapy and diagnosis of prostate cancer
US6867041B2 (en) 2000-02-24 2005-03-15 Xcyte Therapies, Inc. Simultaneous stimulation and concentration of cells
KR20030032922A (ko) 2000-02-24 2003-04-26 싸이트 테라피스 인코포레이티드 세포의 동시 자극 및 농축
US7572631B2 (en) 2000-02-24 2009-08-11 Invitrogen Corporation Activation and expansion of T cells
US6797514B2 (en) 2000-02-24 2004-09-28 Xcyte Therapies, Inc. Simultaneous stimulation and concentration of cells
US7176243B2 (en) * 2000-06-02 2007-02-13 The General Hospital Corporation CaR receptor as a mediator of migratory cell chemotaxis and/or chemokinesis
EP1156062A1 (en) 2000-05-12 2001-11-21 GPC Biotech AG Immunomodulatory human MHC class II antigen-binding peptides/proteins
CA2459136A1 (en) 2001-09-04 2003-03-13 Yeda Research And Development Co. Ltd. A caspase-8 binding protein, its preparation and use
US20050130125A1 (en) * 2002-03-04 2005-06-16 Yuly Zagyansky End of aids for general virology, based on profound science as protein foldings: safe vaccines, universal antimicrobial means, mad cow end
MXPA04010927A (es) * 2002-05-02 2006-01-30 Univ Washington Metodos y composiciones para el tratamiento de enfermedades y trastornos inflamatorios/autoinmunes producidos por linfocitos t en sujetos que padecen una deficiencia en la regulacion de glucocorticoides.
AU2003281200A1 (en) * 2002-07-03 2004-01-23 Tasuku Honjo Immunopotentiating compositions
US7496848B2 (en) 2002-07-22 2009-02-24 Konica Corporation Image forming apparatus and image forming system
US7575925B2 (en) * 2002-12-10 2009-08-18 Sunnybrook Health Sciences Centre Cell preparations comprising cells of the T cell lineage and methods of making and using them
EP3202899B1 (en) * 2003-01-28 2020-10-21 Cellectis Custom-made meganuclease and use thereof
US9982251B2 (en) 2003-03-14 2018-05-29 Cellectis S.A. Large volume ex vivo electroporation method
EP1618891A1 (en) * 2003-03-31 2006-01-25 Kirin Beer Kabushiki Kaisha Method of inducing differentiation and proliferating regulatory t cell by anti-cd52 antibody and medicinal composition therefor
BRPI0417993A (pt) * 2003-12-22 2007-04-27 Genzyme Corp anticorpo anti-cd52 para tratamento da diabetes
US20060194725A1 (en) * 2004-05-07 2006-08-31 James Rasmussen Methods of treating disease with random copolymers
JP2008514702A (ja) * 2004-09-29 2008-05-08 エーエムアール テクノロジー インコーポレイテッド 新規シクロスポリン類似体およびそれらの薬学的使用
CN103710371B (zh) * 2005-08-03 2017-03-01 人类多克隆治疗股份有限公司 表达人源化免疫球蛋白的转基因动物中b细胞凋亡的抑制
KR101527334B1 (ko) * 2005-08-11 2015-06-09 알피 마토씨안-로저스 자가면역 질병의 치료 및 진단용 ｔｃｒ-ｖ-베타 관련 펩티드
WO2007043200A1 (ja) 2005-09-30 2007-04-19 Riken Ｔ細胞分化調節剤
ES2405552T3 (es) * 2005-11-29 2013-05-31 Actogenix N.V. Inducción de tolerancia mucosa a antiantígenos de células beta de islotes pancreáticos
GB0609121D0 (en) 2006-05-09 2006-06-21 Univ Birmingham Peptide Therapy
PL2383297T3 (pl) 2006-08-14 2013-06-28 Xencor Inc Zoptymalizowane przeciwciała ukierunkowane na CD19
WO2008060510A2 (en) * 2006-11-13 2008-05-22 Sangamo Biosciences, Inc. Zinc finger nuclease for targeting the human glucocorticoid receptor locus
US20080131415A1 (en) 2006-11-30 2008-06-05 Riddell Stanley R Adoptive transfer of cd8 + t cell clones derived from central memory cells
EP2123754B1 (en) * 2007-01-30 2011-04-06 Forerunner Pharma Research Co., Ltd. CHIMERIC Fc GAMMA RECEPTOR AND METHOD FOR DETERMINATION OF ADCC ACTIVITY BY USING THE RECEPTOR
US8563314B2 (en) * 2007-09-27 2013-10-22 Sangamo Biosciences, Inc. Methods and compositions for modulating PD1
WO2009091826A2 (en) 2008-01-14 2009-07-23 The Board Of Regents Of The University Of Texas System Compositions and methods related to a human cd19-specific chimeric antigen receptor (h-car)
AU2009288730B2 (en) * 2008-08-25 2013-06-20 Amplimmune, Inc. Compositions of PD-1 antagonists and methods of use
EP2331566B1 (en) 2008-08-26 2015-10-07 City of Hope Method and compositions for enhanced anti-tumor effector functioning of t cells
CA2740077A1 (en) * 2008-10-08 2010-04-15 Cambridge Enterprise Limited Methods and compositions for diagnosis and treatment
US8591905B2 (en) * 2008-10-12 2013-11-26 The Brigham And Women's Hospital, Inc. Nicotine immunonanotherapeutics
US20110030072A1 (en) * 2008-12-04 2011-02-03 Sigma-Aldrich Co. Genome editing of immunodeficiency genes in animals
JPWO2010101249A1 (ja) * 2009-03-06 2012-09-10 国立大学法人三重大学 Ｔ細胞の機能増強方法
EP2411520A2 (en) * 2009-03-27 2012-02-01 Merck Sharp&Dohme Corp. RNA INTERFERENCE MEDIATED INHIBITION OF THE THYMIC STROMAL LYMPHOPOIETIN (TSLP) GENE EXPRESSION USING SHORT INTERFERING NUCLEIC ACID (siNA)
WO2010132697A2 (en) * 2009-05-13 2010-11-18 Genzyme Corporation Methods and compositions for treatment
US20110027881A1 (en) * 2009-07-31 2011-02-03 St. Marianna University School Of Medicine Production method of immune cells
US8586526B2 (en) * 2010-05-17 2013-11-19 Sangamo Biosciences, Inc. DNA-binding proteins and uses thereof
WO2011059836A2 (en) 2009-10-29 2011-05-19 Trustees Of Dartmouth College T cell receptor-deficient t cell compositions
US8956828B2 (en) * 2009-11-10 2015-02-17 Sangamo Biosciences, Inc. Targeted disruption of T cell receptor genes using engineered zinc finger protein nucleases
WO2011072246A2 (en) * 2009-12-10 2011-06-16 Regents Of The University Of Minnesota Tal effector-mediated dna modification
EP2392208B1 (en) * 2010-06-07 2016-05-04 Helmholtz Zentrum München Deutsches Forschungszentrum für Gesundheit und Umwelt (GmbH) Fusion proteins comprising a DNA-binding domain of a Tal effector protein and a non-specific cleavage domain of a restriction nuclease and their use
US20130189759A1 (en) * 2010-07-07 2013-07-25 Cellectis Meganucleases variants cleaving a dna target sequence in the nanog gene and uses thereof
AU2011281062B2 (en) * 2010-07-21 2015-01-22 Board Of Regents, The University Of Texas System Methods and compositions for modification of a HLA locus
US20130315933A1 (en) 2010-10-06 2013-11-28 Christoph Renner Antibodies Directed Against HLA-B27 Homodimers and Methods and Uses Thereof in Diagnosis and Therapy
WO2012050374A2 (en) 2010-10-13 2012-04-19 Innocell, Inc. Immunotherapy for solid tumors
US20130337454A1 (en) 2010-10-27 2013-12-19 Philippe Duchateau Method for increasing the efficiency of double-strand break-induced mutagenesis
PH12013501201A1 (en) 2010-12-09 2013-07-29 Univ Pennsylvania Use of chimeric antigen receptor-modified t cells to treat cancer
KR20140004174A (ko) 2011-01-18 2014-01-10 더 트러스티스 오브 더 유니버시티 오브 펜실바니아 암 치료를 위한 조성물 및 방법
MX363013B (es) * 2011-02-25 2019-03-04 Recombinetics Inc Animales genéticamente modificados y métodos para su obtención.
US9987308B2 (en) 2011-03-23 2018-06-05 Fred Hutchinson Cancer Research Center Method and compositions for cellular immunotherapy
CA3111953C (en) 2011-04-05 2023-10-24 Cellectis Method for the generation of compact tale-nucleases and uses thereof
US20130071414A1 (en) 2011-04-27 2013-03-21 Gianpietro Dotti Engineered cd19-specific t lymphocytes that coexpress il-15 and an inducible caspase-9 based suicide gene for the treatment of b-cell malignancies
CN102836441B (zh) * 2011-06-24 2019-06-11 台北荣民总医院 于感染性与恶性疾病的治疗中提升免疫反应的方法
EP2737066B1 (en) 2011-07-29 2017-11-08 Cellectis High throughput method for assembly and cloning polynucleotides comprising highly similar polynucleotidic modules
MX2014001222A (es) 2011-07-29 2014-09-15 Univ Pennsylvania Receptores coestimuladores de cambio.
CN103946952A (zh) 2011-09-16 2014-07-23 宾夕法尼亚大学董事会 用于治疗癌症的rna改造的t细胞
ES2654060T3 (es) * 2011-10-20 2018-02-12 The U.S.A. As Represented By The Secretary, Department Of Health And Human Services Receptores de antígenos quiméricos anti-CD22
HK1200871A1 (en) * 2011-11-16 2015-08-14 Sangamo Therapeutics, Inc. Modified dna-binding proteins and uses thereof
US10391126B2 (en) * 2011-11-18 2019-08-27 Board Of Regents, The University Of Texas System CAR+ T cells genetically modified to eliminate expression of T-cell receptor and/or HLA
AU2012347919B2 (en) 2011-12-05 2017-02-02 Factor Bioscience Inc. Methods and products for transfecting cells
US20130280220A1 (en) * 2012-04-20 2013-10-24 Nabil Ahmed Chimeric antigen receptor for bispecific activation and targeting of t lymphocytes
BR112014029417B1 (pt) 2012-05-25 2023-03-07 Cellectis Método ex vivo para a preparação de células t para imunoterapia
DK3187586T3 (da) * 2012-08-05 2019-10-14 Absci Llc Inducerbar co-ekspressionssystem
MX367730B (es) 2012-09-04 2019-09-04 Cellectis Receptor de antigeno quimerico multi-cadena y usos del mismo.
AU2013329186B2 (en) * 2012-10-10 2019-02-14 Sangamo Therapeutics, Inc. T cell modifying compounds and uses thereof
US9778269B2 (en) * 2012-11-15 2017-10-03 The Walter And Eliza Hall Institute Of Medical Research Method of treating sepsis by administering a soluble CD52 glycoprotein
DK2956175T3 (da) * 2013-02-15 2017-11-27 Univ California Kimærisk antigenreceptor og fremgangsmåder til anvendelse deraf
US11311575B2 (en) * 2013-05-13 2022-04-26 Cellectis Methods for engineering highly active T cell for immunotherapy
FI2997141T3 (fi) 2013-05-13 2022-12-15 CD19-spesifinen kimeerinen antigeenireseptori ja sen käyttöjä
US11077144B2 (en) 2013-05-13 2021-08-03 Cellectis CD19 specific chimeric antigen receptor and uses thereof
WO2016094880A1 (en) * 2014-12-12 2016-06-16 The Broad Institute Inc. Delivery, use and therapeutic applications of crispr systems and compositions for genome editing as to hematopoietic stem cells (hscs)
US9790490B2 (en) 2015-06-18 2017-10-17 The Broad Institute Inc. CRISPR enzymes and systems
JP6816133B2 (ja) 2015-10-05 2021-01-20 プレシジョン バイオサイエンシズ，インク． 改変ヒトｔ細胞受容体アルファ定常領域遺伝子を含む遺伝子改変細胞
EP3371300A1 (en) * 2015-11-05 2018-09-12 Centro en Investigación Biomédica en Red Process of gene-editing of cells isolated from a subject suffering from a metabolic disease affecting the erythroid lineage, cells obtained by said process and uses thereof
WO2017105110A1 (ko) 2015-12-15 2017-06-22 (주)옵토마인드 광 케이블용 송수신 장치 및 그 정렬 방법
US20190032088A1 (en) * 2016-02-26 2019-01-31 Cellectis Micelle based system nuclease encapsulation for in-vivo gene editing
WO2019016360A1 (en) * 2017-07-21 2019-01-24 Cellectis MODIFIED IMMUNE CELLS RESISTANT TO TUMOR MICRO-ENVIRONMENT
US20230158070A1 (en) * 2018-01-30 2023-05-25 Cellectis Combination comprising allogeneic immune cells deficient for an antigen present on both t-cells and pathological cells and therapeutic antibody against said antigen

Cited By (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11365226B2 (en) 2016-09-08 2022-06-21 2Seventy Bio, Inc. PD-1 homing endonuclease variants, compositions, and methods of use
RU2781083C2 (ru) * 2016-09-08 2022-10-05 2сэвэнти био, Инк. Варианты, композиции и методы применения хоминг-эндонуклеазы pd-1
US11912746B2 (en) 2016-09-08 2024-02-27 2Seventy Bio, Inc. PD-1 homing endonuclease variants, compositions, and methods of use
US12391734B2 (en) 2016-09-08 2025-08-19 Regeneron Pharmaceuticals, Inc. PD-1 homing endonuclease variants, compositions, and methods of use
US12404500B2 (en) 2018-12-10 2025-09-02 Novo Nordisk A/S Homing endonuclease variants
US12577547B2 (en) 2018-12-10 2026-03-17 Regeneron Pharmaceuticals, Inc. PDCD-1 homing endonuclease variants

Also Published As

Publication number Publication date
JP6991167B2 (ja) 2022-02-03
MA37681A3 (fr) 2018-06-29
US11274316B2 (en) 2022-03-15
AU2013266734A1 (en) 2015-01-15
US20210220405A1 (en) 2021-07-22
EP2855667A1 (en) 2015-04-08
US10342829B2 (en) 2019-07-09
NZ703281A (en) 2017-01-27
US20220348955A1 (en) 2022-11-03
DK2855667T5 (da) 2024-10-14
JP2015525065A (ja) 2015-09-03
HK1208879A1 (en) 2016-03-18
US20130315884A1 (en) 2013-11-28
CN104718284A (zh) 2015-06-17
WO2013176916A8 (en) 2014-10-16
JP2019058189A (ja) 2019-04-18
US20210060080A1 (en) 2021-03-04
ES3015120T3 (en) 2025-04-29
SG11201407802WA (en) 2015-01-29
US11603539B2 (en) 2023-03-14
KR20150029651A (ko) 2015-03-18
JP2015523064A (ja) 2015-08-13
WO2013176915A1 (en) 2013-11-28
CN108998418A (zh) 2018-12-14
ZA201409536B (en) 2022-11-30
PL2855667T3 (pl) 2024-03-25
JP6463672B2 (ja) 2019-02-06
US20190216853A1 (en) 2019-07-18
US11007224B2 (en) 2021-05-18
EP4541818A2 (en) 2025-04-23
DK3473707T3 (da) 2025-03-17
US20160145337A1 (en) 2016-05-26
EP2855666A1 (en) 2015-04-08
US20190216854A1 (en) 2019-07-18
AU2018236867A1 (en) 2018-10-18
KR102247979B1 (ko) 2021-05-04
US20220177914A1 (en) 2022-06-09
US20180360883A1 (en) 2018-12-20
ES2962571T3 (es) 2024-03-19
US20180021379A1 (en) 2018-01-25
EP3279315A2 (en) 2018-02-07
KR102437522B1 (ko) 2022-08-26
US11414674B2 (en) 2022-08-16
WO2013176916A1 (en) 2013-11-28
JP2018011603A (ja) 2018-01-25
JP7257749B2 (ja) 2023-04-14
US12577581B2 (en) 2026-03-17
PT3473707T (pt) 2025-04-16
UA118652C2 (uk) 2019-02-25
AU2021201200A1 (en) 2021-03-11
US10363270B2 (en) 2019-07-30
US20140134142A1 (en) 2014-05-15
PL3473707T3 (pl) 2025-04-14
KR20210050590A (ko) 2021-05-07
AU2013266733B2 (en) 2018-07-05
US10517896B2 (en) 2019-12-31
AU2021201967B2 (en) 2024-07-18
BR112014029417B1 (pt) 2023-03-07
US10426795B2 (en) 2019-10-01
CA3133545A1 (en) 2013-11-28
US11891614B2 (en) 2024-02-06
JP6463671B2 (ja) 2019-02-06
CA2874609A1 (en) 2013-11-28
CA2874611A1 (en) 2013-11-28
US20170360835A1 (en) 2017-12-21
EP2855666B1 (en) 2019-12-04
EP2855667B1 (en) 2023-08-09
US20240309397A1 (en) 2024-09-19
CA2874611C (en) 2023-01-24
EP3473707A1 (en) 2019-04-24
AU2021201967A1 (en) 2021-04-29
MY180127A (en) 2020-11-23
EP3276000A3 (en) 2018-02-21
JP6655049B2 (ja) 2020-02-26
MX370265B (es) 2019-12-09
BR112014029417A2 (https=) 2017-08-15
US20200281979A1 (en) 2020-09-10
EP3473707B1 (en) 2024-12-18
US10286007B2 (en) 2019-05-14
MA37681B2 (fr) 2020-07-29
EP3276000A2 (en) 2018-01-31
JP2018183167A (ja) 2018-11-22
MX2014014364A (es) 2015-09-22
MA37681A2 (fr) 2016-06-30
SG10201806573TA (en) 2018-09-27
HK1245321A1 (en) 2018-08-24
EP3964567A1 (en) 2022-03-09
US10874693B2 (en) 2020-12-29
HUE064187T2 (hu) 2024-02-28
IN2014DN10991A (https=) 2015-09-25
AU2018236867B2 (en) 2021-01-21
AR096274A1 (es) 2015-12-16
US20150203817A1 (en) 2015-07-23
CA2874609C (en) 2021-12-07
EP3279315A3 (en) 2018-02-28
HUE070380T2 (hu) 2025-06-28
DK2855667T3 (da) 2023-10-30
AU2013266733A1 (en) 2015-01-15
CA3133545C (en) 2023-08-08
CN111676196A (zh) 2020-09-18
PT2855667T (pt) 2023-11-22
EP4541818A3 (en) 2025-07-23
AU2013266734B2 (en) 2018-11-22
AU2021201200B2 (en) 2023-10-19

Similar Documents

Publication Publication Date Title
EA201492222A1 (ru) Способы конструирования неаллореактивной и устойчивой к иммуносупрессии т-клетки для иммунотерапии
MX380738B (es) Métodos para manipular células t alogénicas, altamente activas para inmunoterapia.
EA201792420A1 (ru) Композиции и способы перепрограммирования tcr с помощью гибридных белков
CY1122720T1 (el) Υποδοχεις τ κυτταρων που αναγνωριζουν περιορισμενη μαgε-α3 μηc ταξης ii
HK1243333A1 (zh) 用於修饰的t细胞的方法和组合物
EA201790953A1 (ru) Изменение экспрессии гена в cart-клетках и их применения
CY1121217T1 (el) Μεθοδοι για συγκομιδη καλλιεργειων κυτταρου θηλαστικων
GB201020995D0 (en) Biological materials and uses thereof
MX2018003534A (es) Proceso de alto rendimiento para identificacion de blanco de receptor de celula t de secuencias de receptor de celula t apareadas de manera natural.
MX2013008375A (es) Anticuerpos anti proteina accesoria del receptor de interleucina-1 y su uso para tratamiento en humanos.
PH12018500965A1 (en) Methods and compositions for gene editing in hematopoietic stem cells
MX2015015638A (es) Metodos para diseñar celulas t altamente activas para inmunoterapia.
MX2020011788A (es) Acoplador trifuncional de antigeno de celulas t y metodos y usos del mismo.
EP3447140A3 (en) Receptor gene for peptide cancer antigen-specific t cell
PH12017501166A1 (en) Antibodies to tight
CR20170032A (es) Moleculas biespecíficas de unión a antígeno activadoras de células t
CR20180162A (es) Moléculas biespecíficas de unión a antígeno activadoras de células t
MX2017012939A (es) Terapias cd20, terapias cd22 y terapias de combinacion con una celula que expresa un receptor quimerico de antigeno (car) de cd19.
MX2017006571A (es) Moleculas de union a antigeno biespecificas activadoras de celulas t.
EA201400254A1 (ru) Биспецифические антигенсвязывающие молекулы, активирующие т-клетки
EP4297036A3 (en) Method for predicting the off-target binding of a peptide which binds to a target peptide presented by a major histocompatibility complex
MX2020009670A (es) Metodos de cultivo por perfusion y usos de los mismos.
BR112014019579A8 (pt) Anticorpos, polinucleotídeos, vetores, métodos de produção de um anticorpo, heteromultímero, método de produção de um heteromultímero e célula hospedeira
BR112012012911A8 (pt) métodos para triar uma molécula capaz de ligação a cd4, para produzir uma composição terapêutica, para triar um anticorpo ou fragmento de anticorpo capaz de ligar cd4, para a produção de um anticorpo ou fragmento de anticorpo in vitro para a ativação de células t regulatórias cd4+cd25+, para tratar um indivíduo, e para triar a presença de células regulatórias t cd4+cd25+ em uma amostra, composição terapêutica, anticorpo ou fragmento de anticorpo, peptídeo isolado, mimótopo de um peptídeo isolado, ácido nucleico, vetor, célula hospedeira ou hibridoma, usos de um anticorpo ou fragmento de anticorpo, do peptídeo isolado e de uma célula t regulatória cd4+cd25+, célula t regulatória cd4+cd25+, e, kit.
MX2016014359A (es) Antigeno e de hepadnavirus marcado y su uso en el tamizado de sustancias antivirales.